¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/3/28 ¤U¤È 11:02:21
²Ä 5183 ½g¦^À³
|
¯à¦b¥þ²y³Ì¤jªº¬ü°ê¥Ö½§¨ó·|2022¦~·|¤W¡A²Ä¤@Ô·Á{§É¤fÀY³ø§i¡C´N¬OÀò¾Ç³N¤WªºªÖ©w¡C
ASLN ¤§«e¥ô¦óÁ{§É结ªG¡A³Ì¦h¥uÀò®ü³ø®iÄý¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2022/3/28 ¤U¤È 07:42:20
²Ä 5182 ½g¦^À³
|
finance-yahoo-com.cdn.ampproject.org/v/s/finance.yahoo.com/amphtml/news/aslan-pharmaceuticals-announces-breaker-presentation-110000585.html?amp_js_v=a6&_gsa=1&usqp=mq331AQKKAFQArABIIACAw%3D%3D#aoh=16484676901202&referrer=https%3A%2F%2Fwww.google.com&_tf=%E4%BE%86%E6%BA%90%EF%BC%9A%251%24s&share=https%3A%2F%2Ffinance.yahoo.com%2Fnews%2Faslan-pharmaceuticals-announces-breaker-presentation-110000585.html |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2022/3/28 ¤U¤È 07:38:52
²Ä 5181 ½g¦^À³
|
finance-yahoo-com.cdn.ampproject.org/v/s/finance.yahoo.com/amphtml/news/aslan-pharmaceuticals-announces-breaker-presentation-110000585.html?amp_js_v=a6&_gsa=1&usqp=mq331AQKKAFQArABIIACAw%3D%3D#aoh=16484674281475&referrer=https%3A%2F%2Fwww.google.com&_tf=%E4%BE%86%E6%BA%90%EF%BC%9A%251%24s&share=https%3A%2F%2Ffinance.yahoo.com%2Fnews%2Faslan-pharmaceuticals-announces-breaker-presentation-110000585.html
½Ð±Ð¤Ñ©R¤j¦³¤£¦Pªº¶i®i§Q¦h¶Ü¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2022/3/23 ¤W¤È 08:57:29
²Ä 5180 ½g¦^À³
|
Â÷60¬ü¤¸ÁÙ»·©O¡I ¤£¹LªY½à¹Lµ{¬O¤@ºØ¼Ö½ì¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2022/3/22 ¤U¤È 11:51:26
²Ä 5179 ½g¦^À³
|
¨S¶q¤pº¦¡A°ª¿³¤Ó¦¤F¡K ¥Ø«e³£ÁÙ¦b´ú©³©O µ¥¥X¶qº¦¨ì1¤¸¥H¤W¦A»¡ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2022/3/22 ¤U¤È 11:04:28
²Ä 5178 ½g¦^À³
|
¦³¨S¦³¬Ý¨ì¡A·à¤l½ñ¥X²Ä¤G°¦¸}¡A ºCºC¯¸°_¨Ó¤F¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2022/3/21 ¤W¤È 11:17:27
²Ä 5177 ½g¦^À³
|
New Clinical Development Success Rates 2011-2020 Report
www.bio.org/clinical-development-success-rates-and-contributing-factors-2011-2020 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2022/3/21 ¤W¤È 11:07:57
²Ä 5176 ½g¦^À³
|
©t¨àÃĤj ¸É¥Rªº¸ê°T¬Û·í§¹¾ã¡A§A»¡ªº¨S¿ù§Ú§è¤Ó»·¤F¡A°Ú©Ç¦Û¤v·Q¤Ó¦h¤F¡A«Ó°¶¤j»¡¦pªG¨È·à±dªÑ»ù¥u·|³Q§ÚÌ´XÓ¥xÆW·à¤Í¼vÅT¨º¤j·§¨S±Ï¤F¡Aªº½T¬O¦p¦¹¡C ¨È·à±d003¤W¥b¦~¥ý±Ò°Ê¼ìºÅ©Ê¤j¸zª¢IBD ¤G´ÁÁ{§É¡A¦ÛÅé§K¬Ì ¤Þ°_ªº¥Ö½§¯f¤]¦³¦b³W¹º¬ã¨s¤¤¡A¦b©Ò¦³ÃĪ«¤G´ÁÁ{§É¬O¥¢±Ñ²v³Ì°ªªº´Á§O¡A¤£¹L¦b¤G´ÁÁ{¦¨¥\¾÷²v¤è±¥Ö½§¯f»P¨ä¥L¤£¦P¯e¯f»â°ì¤ñ¸û¦¨¥\¾÷²v¬O³Ì°ªªº ¥Ö½§¯f¦Ê¤À¤§48.1 ºë¯«¬ìÃĪ«¦Ê¤À¤§26.8 Àù¯gÃĪ«¦Ê¤À¤§24.6 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2022/3/20 ¤U¤È 07:32:13
²Ä 5175 ½g¦^À³
|
¨S¨Æ¨S¨Æ...¦pªG¨È·à±dªÑ»ù¥u·|³Q§ÚÌ´XÓ¥xÆW·à¤Í¼vÅT ¨º¤j·§¨S±Ï¤F µo¨¥¦hªÅ©ê«èÃø§K...¦ý¤j®a³£¬O§Æ±æ¨È·à±d§ó¦n ©Ò¥H¤j®a©M®ð¥Í°]³á |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2022/3/20 ¤U¤È 05:43:40
²Ä 5174 ½g¦^À³
|
¥xÁÞ¤j¡A±z§è»·¤F¡A¨S¦³µo¨¥ªÌªº¦WºÙ¬O·|ÀH·N§ó°Êªº¡A¬O´£¿ô±z¤£n®³§O¤Hªº¦WºÙ¶}ª±¯º~~¦Ü©ó±z©Ò´£¡Aªº½T¬O¥i¥H§ó·s¡A°¨¤W§@·~~~~~
To:ª©¥D¤j¤j¡A³Â·Ð±z¼W¥[¦b¥»ª©ªº¼ÐÃD¸Ì±¦p¤U :
2022.01-¤@´Á¼Æ¾Ú¤§Àu¤Æ²³ø(Y¥h¦~¤E¤ë®³³oª©À³¸Ó·|¦n¤@ÂI):ir.aslanpharma.com/static-files/2a7f1481-a0b3-47d1-87ef-e6ed30321475
2022.01-KOL²³ø:ir.aslanpharma.com/static-files/379e7107-c421-4401-b035-e43c4b682d19 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2022/3/20 ¤U¤È 03:51:45
²Ä 5173 ½g¦^À³
|
©t¨àÃĤj §Ú¥u¥H£¸Ó´¶³qª©¤ÍÂI¥X°ÝÃD©Ò¦b¡A¬O¬°¤j®a¦n¤£¬O¬°§ÚÓ¤H¡Aª©¥D¤£±µ¨ü¡A§Ú¤]»{¤F¡A·íª©¥D©ñªº¸ê®Æ¹L®É¦³¤H´£¿ôÀ³¸Ó¥Î·PÁ»P§ó¤jªº¥]®e¤ß§ó¥¿¤~¹ï¡A¥H«e¨È·à±d¬ãµoÁx¹D¬O©t¨àÃÄ¡A²{¦b¬ãµoªº¤£¬O©t¨àÃÄ¡AÅýª©¤Í¨C¤Ñ¥´¶}ª©±´N¦^¨ì¥¢±Ñªº°O¾Ð¡A³o¹ïª©¤Í¤½¥¶Ü¡H ¦b¤Ñ©R¤j¶}¤@Ó·sª©¦³·s®ð¶H§Ú¤~·|¦A¯d¨¥¤À¨É¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/3/20 ¤U¤È 02:05:28
²Ä 5172 ½g¦^À³
|
³Ìªñ¹ï¦Ñ·àªí²{¦³ÂI¥¢±æ¤Îªq³à
ÁöµMª¾¹D¦Ñ·ànªø´Á§ë¸ê ¥u¤£¹L±q1b¼Æ¾Ú»¡©ú«á ¤£ºÞ¤½¥q¨Æ«á¦³¦ó»¡©ú¤Î§@¬° ¥«³õ¬Ò¤£»{¦P ¦Ü¤µè¦n³s¶^6Ó¤ë
¬J¤w¤W²î´Nµ¥@¤ß¤U²îªº®É¾÷
½Ð¤Ñ©R¤j¡A¯àÄ~Äò¤ÀªR¤Î¤À¨É¥Ø«eÁ{§É¶i«×©Î®ø®§
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2022/3/20 ¤W¤È 12:25:45
²Ä 5171 ½g¦^À³
|
©t¨àÃÄ´N¬O¤jÃÄ¡A³o¥i´N§O¶Ã§ï¡I ¤j®a³£§Æ±æªü·à¦n¡A ªü·à¦n¡A¤j®a´N·|¦n¡I
¥¿©À´N·|¦³¦nµ²ªG¡]¤j³¡¥÷¡A«¢¡I¡^ n¹³¤Ñ©R¤jÂàzª÷è¸g»¡ªº¡G ⋯¤Z¨£½Ñ¬Û«D¬Û¡A«h¨£¦p¨Ó¡I
§Ú¬O·s·à¤Í¡A¦¨¥»¤j·§¦b2¶ô¦h¡A ÁöµM²{¦bªÑ»ù°÷§C¡A¤£¹L¡A¤]¤£·|·Q¦A¼W¥[¡A °µÓ§Ö¼Ö§ë¸ê¤H¡A¤£nÅý§ë¸êÀ£¢¦Û¤vªº¥Í¬¡¡A©ã¨®a¡A¨º´N«Ü¤£§´¡I
¬ü¹Ú¦¨¯u¡A»Ýn®É¶¡¡A¤£nÅý½Ñ¬Û·Î¼õ¡A ®É¶¡·|¬OÀò§Qªº¦nªB¤Í¡I ¹Ú·Q¡ã¤£¥¿¬O¤@Ó¦³¸`«×§ë¸ê¤HÀ³¦³ªºÃh©ê¡ã Ä@¡ã§Ṳ́j®a³£¦³¦nµ²ªG¡I
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2022/3/19 ¤U¤È 10:52:13
²Ä 5170 ½g¦^À³
|
¥xÁÞ¤j¡A½Ð±z©ñ´L«ÂI¡A¥»ª©¤WÁÙ¨S¦³¤H·|®³µo¨¥ªÌªº¦WºÙ¶}ª±¯º³á~¦pªGı±o¥»ª©¤£°÷¥¿±¡A¥i¥H¥t¶}¤@ª©¡A»¡¤£©w·|¹ïªü·àªº«e³~§ó¦³À°§U¡C
ı±o«e³~ÁÙºâ¥ú©úªº©t¨àÃÄ ÂÔ¤W |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2022/3/19 ¤U¤È 09:17:30
²Ä 5169 ½g¦^À³
|
§O¦A¥s©t¨àÃĤF ¥s¤jÃĤ]³\«e³~·|¥ú©úÂI¡A ¦A©t¨àÃĤU¥h¡A´Nw¦b¦a¤W¤F¡A «¢⋯«¢⋯
2022.01- ¦³¤½¥q·s²³ø ¥i¦A¼W¦C¶i¥h
2021.09-¤@´Á¼Æ¾Ú²³ø:ir.aslanpharma.com/static-files/da4bc98e-9b9d-4add-8d6b-b66b427f76e8 ( «O ¯d )
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2022/3/19 ¤U¤È 07:53:25
²Ä 5168 ½g¦^À³
|
§O¦A¥s§b·à¤F¡A ¥sªü·à¤]³\«e³~·|¥ú©úÂI¡A ¦A§b¤U¥h¡A´Nw¦b¦a¤W¤F¡A «¢⋯«¢⋯ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2022/3/19 ¤U¤È 02:15:22
²Ä 5167 ½g¦^À³
|
§b·à¨üÁܦ~«×¥Ö½§¦~·|²³ø~³o¬O¦UÃļtªºRD·|°Ñ¥[ªº·|¡A§Æ±æ¯à§l¤Þ¤j¼tªº¥Ø¥ú¡A¥[ªo¡AªÑ»ù§O¦AµäÃû¤F~~~~ www.streetinsider.com/dr/news.php?id=19795057&gfv=1 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2022/3/18 ¤U¤È 10:08:13
²Ä 5166 ½g¦^À³
|
¤µ±ß¡ã §Æ±æ¶}©l¬ü¦n¡I ¶}½L»á¦³§áÂàÁͶդ§«º¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/3/18 ¤U¤È 04:50:55
²Ä 5165 ½g¦^À³
|
ÅÞ¿è«ä¦Ò¡G ¤À¨â¬£ (¤@)¬Ý¦nASLAN004¤G´ÁÁ{§Éµ²ªG(»{¦P¤½¥q¬£)¡G ¤½¥q¬Ý¦n004¤G´ÁÁ{§Éµ²ªG¡An§@¤T´Á¡A¯Ê¸êª÷¤@©w·|éwªÑ»ù¡C¦pªG¤U¥«n¦p¦ó¶Ò¸ê??? (¤½¥q²{¦³¸êª÷°÷¥Î¨ì©ú(2023)¦~©³) (´î¸ê¤@¥b?²bÈ¥[¿?ªÑ»ù¥[¿?)
(¤G)¤£¬Ý¦nASLAN004¤G´ÁÁ{§Éµ²ªG(¤£»{¦P¤½¥q¬£)¡G ASLANªºªÑ²¼¨ä¹ê²{¦b´N¥i¥H½æ¥X¤F(¦]¬°¾á¤ß¸Ñª¼¥¢±Ñ)¡C (¤£«HMOA???ÅÞ¿è???) (¨Ó¤£¤Î¸Ñª¼´N¤U¥«???) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/3/17 ¤U¤È 07:37:00
²Ä 5164 ½g¦^À³
|
¥un¤£p±o¥¢ ¥Î¶~¿ú§ë¸ê
¥Î®É¶¡µ¥«Ý
§Ú»{¬°ÁÙ¦³¾÷·|
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2022/3/17 ¤U¤È 01:44:52
²Ä 5163 ½g¦^À³
|
²{¦bÁÙ´±¶R¦Ñ·àªº¯uªº²r ¨}¤ß«Øij¯uªºn½ä¤£¦p®³¥h½ä´äªÑ³°ªÑ §ë¸ê¦Ñ·à³oµ§¿ú§Ú¤w¸g¤£´Á¤£«Ý¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2022/3/17 ¤W¤È 09:08:38
²Ä 5162 ½g¦^À³
|
¦Ñ·à¤Í·P¨ü¨ì±o¬O¦M¾÷,ªñ´Á¥[¤Jªº·à¤Í¬Ý¨ì¬OÂà¾÷°Ú~~~´N¹³§Ú,´Nºâ§b·à¨â¦~«áº¦8¿,¤]¬OµL·P, ¥[ªo°Ú~~~¤O¨D·l¯q¥X³õ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GMomen10144830 |
µoªí®É¶¡:2022/3/16 ¤U¤È 03:30:52
²Ä 5161 ½g¦^À³
|
news.cnyes.com/news/id/4798953
¤¤°ê½u¤W©Ð²£¥æ©öªA°È¥¥x©Ð¦h¦h (Fangdd Network Group Ltd)(DUO-US) ¥¿±Á{¤U¥«¦M¾÷¡C
¸Ó¤½¥qµo§G¤½§i«ü¥X¡A¤w¦¬¨ì¯Ç´µ¹F§J¤W¥«¸ê®æ³¡ 4 ¤éµo¥Xªº³qª¾¡A¥Ñ©ó±q 2021 ¦~ 11 ¤ë 19 ¤é¦Ü 2022 ¦~ 1 ¤ë 3 ¤é¡A©Ð¦h¦h ADS ¦¬½L»ù³sÄò 30 Ó¥æ©ö¤é§C©ó¨CªÑ 1 ¬ü¤¸¡A¥¼º¡¨¬¯Ç´µ¹F§J¤W¥«³W«h 5450 ¤¤³W©wªº³Ì§C»ùn¨D¡C
©Ð¦h¦hªí¥Ü¡A¸Ó¤½¥q¤wÀò±o 180 Ó¥æ©ö¤éªº¼e´Á¡A¨ì´Á¤é¬° 2022 ¦~ 7 ¤ë 5 ¤é¡C¦pªG¦b³o 180 ¤Ñ´Á¶¡¤º©Ð¦h¦h ADS ¦¬½L»ù¦Ü¤Ö³sÄò 10 Ó¥æ©ö¤éºû«ù¦b 1 ¬ü¤¸¥H¤W¡A¸Ó¤½¥q±N²æÂ÷¤U¥«Æ[¹î¦W³æ¡F¦pªG¦b 180 Ó¥æ©ö¤é¤º¤´¥¼¹F¼Ð¡A¤´¥i¦Aª§¨úÃB¥~ªº®É¶¡¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2022/3/16 ¤U¤È 12:42:03
²Ä 5160 ½g¦^À³
|
§â004 Á¿ªº¦³¦h¦n·|¦³«Ü¤j·ÀI, §Ú¥H«e¤@ª½±j½Õ¦³¦h¤Ö¼Æ¾Ú»¡¦h¤Ö¸Ü,¼Æ¾Ú¦³¦h¦n¹Ú·Q¤~¯à¦³¦h¤j, ¤Ï¦Ó§åµûÂI¥X¯ÊÂI, ¤£»{¬°¤½¥q¥¼¨Ó·|«Ü¦n¦³¤@¤Ñ¼Æ¾Ú¥X¨Ó«ÜÅåÆA, ±i¤O°÷¤jªÑ»ù¤Ï¦Ó·|¤jº¦
ASLAN PHARMACEUTICALS ¥ô©R¥Ö½§¬ì¸ê²`Âå¥Í ALEX KAOUKHOV ³Õ¤h¬°º®uÂåÀø©x 1 ¦b¬ü°ê©M¼Ú¬w¾á¥ô°ª¯Å¥Íª«»sÃľ°È¶W¹L 20 ¦~ªº¥Ö½§¬ìÂå¥Í¡A¥]¬A¦b Almirall¡BAllergan ©M Novartis ªºÂ¾¦ì ÀHµÛ eblasakimab¡]¤]ºÙ¬° ASLAN004¡^¶i¤J«á´Á¸ÕÅç¡A¥[±j¤F»â¾É¹Î¶¤ Alex ³Ìªñ¾á¥ô Bioniz Therapeutics ªºÁ{§É¶}µo¥DºÞ©M°ª¯Å°ÆÁ`µô«Ø¥ß¨ÃºÞ²z¤@ӹζ¤¡At³d¶}µoªvÀø¥Ö½§ªºªvÀø¸ê²£ ©MG¸z¹D¦Û¨§K¬Ì©Ê¯e¯f (IBD ) ¦b¦¹¤§«e¡A±q 2018 ¦~¨ì 2020 ¦~¡AAlex ¾á¥ô Almirall ªº¥þ²yµo®i¥DºÞ¡C¥LªºÂ¾³d¥]¬A¥þ²yÁ{§É©M«DÁ{§É¶}µo¡A¦¹¥~ÁÙ¬°»P¥H¤U¬ÛÃöªº·~°È¶}µo¬¡°Ê°µ¥X°^Äm «Ø¥ß¤½¥qªºÂå¾Ç¥Ö½§¯f¾ÇºÞ¹D¡A¥]¬A¦b¼Ú¬wÀò±o lebrikizumab ªº³\¥i¡C Alex ÁÙ¬O¬ü°ê¦ãº¸«Ø (Allergan) ªºÁ{§É¶}µo°ÆÁ`µô¡At³dºÊ·þÂåÀø¥Ö½§¬ìºÞ¹D¡C¦b¦¹¤§«e¡A¥L´¿¦b¿ÕµØ©M°ª¼w¬ü¾á¥ôÁ{§É¶}µo»â¾É¾°È¡C¦b¥LªºÂ¾·~¥Í²P¤¤¡AAlex ³]p¨Ã»â¾É¤F¤j«¬Á{§É¸ÕÅç¡AÀò±o¤F¦h¶µ¥þ²y²£«~§åã
¤G´ÁÁ{§É¬O¥¢±Ñ²v³Ì°ªªº´Á§O, ¤½¥q´«¦³¸gÅ窺Âå¾Çªø, Åý (AD 004 ) (IBD 003) ¬ãµo¦¨¥\, ¬Ý°_¨Ó¬O¨S¬Æ»ò¤£¦n
©ú¤Ñ¤j¥ý«e´£¦@¸ê°T «ö·Ó³W©w¡A¥ô¦ó¤@®a¯Ç´µ¹F§J¤W¥«¤½¥q¦pªG¦b³sÄò30Ó¥æ©ö¤é¤º¡AªÑ»ù§C©ó1¬ü¤¸¡A±N·|¦¬¨ì¨Ó¦Û¯Ç´µ¹F§J°lÂܳo®a¤½¥qªº³ø§i¡Aµ¹¤©¬°´Á90¤ÑªºÄµ§i¡F¦pªG¸Ó¤½¥q¦b90¤Ñĵ§i´Á¤º¤´ÂµLªk§ïÅܲ{ª¬¡A¤]´N¬O¡GµLªk¦b³o¬q´Á¶¡¦³³sÄò10Ó¥æ©ö¤é¨ÏªÑ»ùªð¦^¨ì1¬ü¤¸¥H¤W¡A³o®a¤½¥q´N·|³QºKµP À³¸Ó§Ö30¤Ñ¥¼¹F1¬ü¤¸ ? ³o¬O¤j®anª`·Nªº¨Æ (¬Ý°_¨Ó§ë¸ê¾÷ºc¹ï¤@´Á¼Æ¾Ú «H¤ß¤£¨¬ ¤£¶R³æ )
ASLAN 004¤@´Á¼Æ¾Ú ASLAN 004 ¤@´ÁÁ{§ÉIGA 0/1 PÈ¥¼¹F¼Ð ( dupilumab ¤@´ÁÁ{§ÉIGA 0/1 PȤ]¥¼¹F¼Ð ) ASLAN 004 EASI-75 ¤@´ÁÁ{§ÉPȹF¼Ð , EASI-90 PÈ¥¼¹F¼Ð (dupilumab ¤@´ÁÁ{§ÉEASI-75 EASI-90 PȤ]¥¼¹F¼Ð)
¬ü°ê¬Ì±¡¤w¤U°¨ì¨¦©³, ·s¥[©Y¬Ì±¡¥H¶}©l¤U°, ¿D¬w¬Ì±¡¤U°¤T¤À¤§¤G , ¥¼¨Ó¦³§Q¦¬®×ªº³t«×
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/3/16 ¤W¤È 08:40:37
²Ä 5159 ½g¦^À³
|
¨È·à±d004 2bÁ{§É¸ÕÅç¶i¦æ¤@¥b®É ¥DÂåÀø©x°}«e´«¤H ³o¥Nªí¤°»ò·N¸q ¥Nªí¤½¥q¥X²{«Ü¤jªº°ÝÃD
¥DÂåÀø©x¬O¤½¥q¤¤³ÌÀ´·sÃĪº¤H ¿ï¾Ü¦b¦¹®ÉÂ÷¶}¤F ¥i¯à¬Oµo²{¤F°ÝÃD¡A¤Î¬Ý¤£¨ì¥¼¨Óªº§Æ±æ¤Î§Q¯q
ªÑ¥«¥Ã»·¬O¹ïªº ¤µ¦¬üªÑ¬O¥H¤j¶^9%¦¬³õ
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/3/16 ¤W¤È 06:47:17
²Ä 5158 ½g¦^À³
|
¶R¨È·à±d¯u¬O¿ù»~ªº¨M©w
³o®a¤½¥q¤S¦³·sªºCheif Medical Officer ¤£ª¾¦b·d¤°»ò¡AÁÙ¬O¤S¹J¤°»ò§xÃø¡A°}«e´«±N¡A ³o®a¤½¥q¥i¯à¯uªº¦³°ÝÃD |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬}±x10144818 |
µoªí®É¶¡:2022/3/10 ¤W¤È 10:47:40
²Ä 5157 ½g¦^À³
|
¥h¦~©³©¿µM·Q°_·à¤l¤W¥««á¶]¥hþ¤F¡A«á¨Ó¤~µo²{ì¨Ó¸ú¥h¬ü°ê¡A è¦n¦³½Æ©e°U´N°Ñ»P¤@¤U¡A¹L¦~«e¥Î¤F888ªÑ¨Ó¤p½ä©y±¡^_^
¤£ºÞþ¶¡·sÃÄ´N¬OÓ½ä¡A¬JµM¬O½ä·íµMn¥Î¶¢¿ú¡A ½ä¿é¥s¥¿±`¡A½äĹ·|«Ü²n |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§ë¸ê¬ö«ß10145266 |
µoªí®É¶¡:2022/3/9 ¤U¤È 10:56:44
²Ä 5156 ½g¦^À³
|
«Ó°¶¤j
Ó¤H¤â¤W1¸U¦hªÑ
¦b¦Ñ·à¥xÆW¤U¥««e¼Æ¤é¶R¶i¤@³¡¥÷
ªñ´Á¶^¸¨0.85¥H¤U«á¡A«ùÄò¦A¶R¶i
²{¦¨¥»§C©ó1¬ü
¹ï©ó¦Ñ·à¡A¤p§Ì¬Ò¬O¥H¨ä¾l¼ÐªºÀò§Qª÷Âà¶i
Y¤£©¯¥¢±Ñ¡A¤F¤£°_´N¬O¥ý«eªºÀò§Q°µ¥Õ¤u¦Ó¤w¡A³oÓ·ÀIÓ¤H¯à©Ó¨ü
¥H¤W |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2022/3/4 ¤W¤È 10:18:56
²Ä 5155 ½g¦^À³
|
À£¤O¤Ó¤j¡A¦³Ãª°·±d¡A Áȱo°]´I¡A¿é±¼°·±d¡A±o¤£Àv¥¢¡I ¶q¤O¦Ó¬°¡I µ½·N´£¿ô¡A²ö¨£©Ç¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦N10151329 |
µoªí®É¶¡:2022/3/4 ¤W¤È 09:44:14
²Ä 5154 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2022/3/4 ¤W¤È 08:53:06
²Ä 5153 ½g¦^À³
|
¤£ª¾¹D¤j®a¤â¤WÁÙ¦³¦h¤Ö¨È·à±d«ùªÑ? §Ú¦Û¤v±q³Ì°ª«ù¦³40000ªÑ(¥xÆW·à200±i) «á¨Ó¦³ºCºC´î½X¤@¥b¡A²{¦b¤â¤WÁÙ¦³20000ªÑ ³o20000ªÑ§Ú¤]¤£¥´ºâ°Ê¤F¡A¤]¦³¥þ³¡½ß¥úªº¤ß²z·Ç³Æ §Ú¤j³¡¤Àªº¸ê²£³£¦b¥xªÑ¤Î³¡¤Àéwªº¬üªÑ ©Ò¥H²{¦b´X¤Ñ¤~·|¥h¬Ý¨È·à±dªÑ»ù¤@¦¸
¤j®a¤d¸U§O«À£¡A©êµÛ¤@¤ÁÀH½tªº¤ßºA ¤~¦³¿ìªk¼õ¹L¨È·à±d³o³Ì«á¤@µ{(¤£ºÞ³Ì«á¦¨¥\©Î¥¢±Ñ)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/3/4 ¤W¤È 08:49:58
²Ä 5152 ½g¦^À³
|
³Â·Ð¤Ñ©R¤j ½Ð§A¤ÀªR¤@¤U 004 1b¸ÕÅç®É¡A¤½¥q¸Ñª¼¼Æ¾Ú¦³¦ó¤£§Q¡A¦¬®×¸ÕÅçªÌ¿ï¾Ü¦³¦ó¥¢µ¦¤§³B
2b ¸ÕÅç¥Ø«e¦³¶i®i¶Ü¡A·|¨ü«X¯Q¾Ôª§¼vÅT¶Ü
§ÚÌ»Ýn¤@ÂI¥¼¨Óªº§Æ±æ Åý¦Ñ·à¤Í̼µ¦í ·PÁ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§ë¸ê¬ö«ß10145266 |
µoªí®É¶¡:2022/3/3 ¤U¤È 04:13:05
²Ä 5151 ½g¦^À³
|
¥un¤½¥q¦³¸êª÷¯à«ùÄò±À¶iÁ{§É
Ó¤H·|«ùÄò¥[½X
004¤@´Áªº¦¬®×miss¡A¤½¥q¤]¤w¹ïµ¦
¶V±µªñ¤G´Á´Á¤¤¤ÀªR¡AªÑ»ù²zÀ³¹ïÀ³¦X²z»ù¦ì
·íµM¡A¦¹¶È¬°Ó¤HÁr´ú
¦Ñ·à¡A¥[ªoÅo |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦N10151329 |
µoªí®É¶¡:2022/3/3 ¤W¤È 09:29:43
²Ä 5150 ½g¦^À³
|
¬üªÑ¤jº¦590...¥LÁÙ¬O¶^~¦n¨S¤O |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/3/3 ¤W¤È 08:26:26
²Ä 5149 ½g¦^À³
|
¦U¦ì¤j¤j §Úı±o¨È·à±d¯uªº¤K¦r¤£¦n
004¤@´Á¸ÕÅç´Á¶¡¡A¹J¨ì¤F·s«aªÍª¢ °ª®p¡A°ÑÉO¸ÕÅçªÌªº¦æ°Ê·|¨ü¬ù§ô¡A ©Î¦h©Î¤Ö·|¼vÅT¸ÕÅç¬yµ{¶¶ºZ
004¤G´Á¸ÕÅç¡A¤S¹J«X¯Q¾Ôª§¡A³y¦¨¥þ¥@¬É¸gÀÙª÷¿Ä°ÊÀú¡A¬Æ¦Ü¥i¯à¤Þ°_¥@¬Éªºx¨Æ½Ä¬ð
¯uªº¤£ª¾¦p¦óÀ³¹ï¡A¥u¯à©ñ¤U¶¶¨ä¦ÛµM
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2022/3/3 ¤W¤È 06:23:57
²Ä 5148 ½g¦^À³
|
²H©w ¥u¶i¤£¥X¡An¤U¥«³qª¾§Ú¨Ó¾Þ©³ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gonly10135877 |
µoªí®É¶¡:2022/3/2 ¤U¤È 11:48:24
²Ä 5147 ½g¦^À³
|
Y¨«¤W´î¸ê¤]¦n,ªÑªFÅv¯q¤£ÅÜ,¦ýªÑªF¥Iªºadr ºÞ²z¶O´î¤Ö |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2022/3/2 ¤U¤È 11:43:35
²Ä 5146 ½g¦^À³
|
¨Ó³o¸ÌÁ¿·²D¸Üdunk¤£¥² »P¨ä³o»ù¦ìn½æ¥X¡A´N©ñµÛ·í¼Ö³z¤]¦n ¤Ï¥¿¤j®a¤]¦¤w¦³³ÌÃa¥´ºâ¤F°Õ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2022/3/2 ¤U¤È 11:16:14
²Ä 5145 ½g¦^À³
|
¤§«e¥»¤Hªº¯d¨¥³£¤w¸g¤@¤@ÅçÃÒ.......ªÑ»ù¤w¸g©¹0.8¾aªñ ! ±µ¤U¨Ó·|ºCºC¤U±´¨ì0.4¥ª¥k ! ³ÌºGªº¬O¦pªG30¤Ñ¤ºªÑ»ù³£¯¸¤£¤W1¶ô¿ú~ÁÙn±Á{¤U¥«·ÀI ~ ¤£¹L¬üªÑ«Ü¬y¦æ¤À©îªÑ²¼´î¤Ö§AªºªÑ¥÷µM«á¼W¥[ªÑ²¼±È¨ÓÁקKªÑ²¼¤U¥«...§Æ±æ¨È·à±d¤£n¨«¨ì³o¤@¨B
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2022/1/19 ¤W¤È 09:59:39²Ä 5061 ½g¦^À³ ¶ZÂ÷¤W¦¸¯d¨¥(2021/12/28)¹L¤F¤j¬ù20¤Ñ~¨ì¤F¤µ¤Ñ¥Ø«e¤w¸g¶^¸¨1¶ô¤§¤U... (2021/9/29)¸Ñª¼¤j¶^¤§®ÉÁÙ¦³2.5¶ô,¥B·í®É¥»¤H¤w¸gÂ_¨¥¤§«áÁÙ·|«ùÄò¤j¶^... ¬Ýªk¨Ì¤£ÅܱNÄ~Äò©¹0.8¾aªñ~¦A¨Ó´N¬O©¹0.5»ù¦ì¾aÃl.... ¤d¸U¤£n¬Û«H±Ë»ò³o·sÃĤñ±Ë»òÁÙn¦nªº°¸Ü ? §Aª¾¹D¥«±¤W¾AÀ³©Ê¥Ö½§ª¢·sÃĦ³¦h¤Ö¶Ü ? ª¾¹D¤F§A´N¤£·|Ä~Äò§ë¸êASLN¤F....
³¯¤j§Aªºµo¨¥¨S¦³°ÝÃD~¤£»Ýn³Q¤H«Â¯Ù~~¤]¤£·|¦³ªk«ß³d¥ô !
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/12/28 ¤U¤È 01:43:58²Ä 5008 ½g¦^À³ ¥H¤U¬O2021/9/29¸Ñª¼¨ì¤µ¤Ñªº¬Ýªk.... ¥»¤H1´Á¸Ñª¼¤j¶^·í¤Ñ¬å¥X»ù¦ì2¶ô5¥ª¥k!!¨ì¤µ¤Ñ¤S¶^¨ì1¶ô¿ú¤W¤U~²{¦bªºªÑ»ù¤w¸gÅçÃÒ·í®Éªº¬Ýªk~ ¤§«áÁÙ·|©¹0.8¾aªñ~¤£«H¶Ü ? ½Ð±µµÛ¬Ý !! ºô¸ô°g´öªGµMÁÙ¬O·|¨R©ü¤@°ï¤H°Ú~½Ð¦Û¤v¤p¤ß!!
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/23 ¤U¤È 05:55:34²Ä 4784 ½g¦^À³ ¬Q¤é«ùÄò¤j¶^7%¤¤~«Ü¼y©¯¥»¤H¦b¨È·à±d¬ü¤Æªº1´Á¸Ñª¼¼Æ¾Ú..¦ý¥«³õ¤£»{¦P¤j¶^«á...¦b2¶ô¦h´N¥þ¼Æ¥X²æ.. ¤§«e¤w¸g»¡¹LªGµM¤j¶^«áÁÙ·|«ùÄò³Ð·s§C...¥¼¨Ó±NºCºC½w¶^¨ì¤@¶ô¤§¤U..¤d¸U¤£n¤£¬Û«H ?
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/15 ¤U¤È 07:49:46²Ä 4750 ½g¦^À³ ¥H¤U§ó¥¿¬°004 ¤j®aÁÙ°O±o¶Ü¡H ¨È·à±d³£¬O¤@³eªº§@·¡A¤§«eÁx¹DÀù¤T´Á¥¼¸Ñª¼¤§«e¤]¬O³£«Ü¼ÖÆ[¡AµM«á³oÃ䪺ºô¤Í±M·~¤ÀªR¤å³¹³sµo¡I»¡¦³¦h¼F®`¤@©w·|¹L¤T´Á¡Aµ²ªG¤@¸Ñª¼¥¢±ÑªÑ»ù¤j¶^¡A³oÃ䪺ªº°l±·¤å³¹ÃÒ¾Ú¤]³£¤@°_¬å±¼¤F¡AµM«á²{¦b¦A¨ÓÓ004¡K ¬Ý¦ü«Ü±M·~¼Æ¾Ú¤å³¹Ä~Äò°l±·¡A¦ý¨Æ¹ê004´N¬O¼Æ¾Ú¤£¦n¡AÃø¤£¦¨¨gµo¬Ý¦ü±M·~ªº¤å³¹¡A¨È·à±d´N·|ùL¤G´Á¶Ü¡HµM«á³Q¦¬ÁÊ¡H ·í§½ªÌ°g¡A®ÇÆ[ªÌ²M¡A½Ð¤T«ä¡K
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/12 ¤U¤È 03:24:19²Ä 4709 ½g¦^À³ Ó¤Hı±o³o¦¸¤£¬OÀ£§C¥X³f¸ÑŪ, ¦U¦ì¦³¬Ý¹L¼Æ¾ÚÀu¦ý¬OªÑ»ù¶^±¼¤@¥bªºªº¨Ò¤l¶Ü? ³q±`¼Æ¾ÚÀu³£¬Oº¦¤@¿!¤£·|À£§CÅý§A¦Y³fªº©Ô! ¨S·N¥~ªÑ»ù·|½w¶^¨ì1¶ô¤§¤U~
¥H¤U¬O9¤ë©³ªº¬Ýªk¦Ü¤µ¤£ÅÜ...½w¶^¨ì§A¤ß·W·N¶Ã...
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/6 ¤W¤È 08:53:03²Ä 4663 ½g¦^À³ ¥H¤U¬O 9/29 ªº¬Ýªk ¦Ü¤µ¤£ÅÜ
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/9/29 ¤W¤È 09:06:30²Ä 4559 ½g¦^À³ ¬Û«H¶R¨È·à±dªº¦U¦ì¤j¤j,¥¼¶}¼ú¤§«e³£¦bÀqÀq½Lºâ,§Úªº¦Ê¸U§ë¸ê¦b¤E¤ë¸Ñª¼«á·|½¦¨¦n´X¿·Ç³Æ¶R¨®¶R©Ð¤F,¦ý³o¦¸¶}¼úµ²ªG´N¬O¤£¦p¹w´Á,§Ú¥i¥H§i¶D¦U¦ì°ê¥~¦U§ë¸ê¶R®a¹Î¶¤¬O¤£¶R³æªº,¤]¤£n¬Û«H±Ë»ò§ë¸ê¾÷ºcµ¹¥Ø¼Ð»ù8¶ô¿ú(³o¨Ç³£¬O½æªÅªº¦nªB¤Í,§Aªº¿ú³£¬O³Q³o¨Ç½æªÅªÌÁȨ«)! °ê¥~ªº§ë¸ê¹Î¶¤¤£¬Oªxªx¤§½ú,I«á¬ã¨s¹Î¶¤ªº¥\¤O¤£ª¾¹D±j¹L³oÓª©ªº¬Y¨Ç¤ÀªR¼Æ¦Ê¿!¤]¤£·|¸ò§AºtÀ¸..¦n¼Æ¾Ú´N¬O¤j¶R,Äê¼Æ¾Ú´N¬O¤j½æ! ¦pªG¯uªº¹Ú¿ô¤F´NÅý¥L¿ô§a,¤d¸U¤£n¨I¾K¦b¹Ú¸Ìn¶}©l¾Ç·|±¹ï²{¹ê ! ¬üªÑºD©Ê¦pªG¤j¶^«áªº¹j¤ÑÁÙ¬O¤j¶^,¤§«áªº¼Æ©P±N·|«ù³Ð·s§C,¤£«H¶Ü ?11¤ë1¤é¤j®a¨ÓÅçÃÒ !
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/6 ¤U¤È 02:49:51²Ä 4668 ½g¦^À³ ¥«³õ¤W°µÃþ¦üªºÃįuªº¤Ó¦h¤F~³Ìªñ1¦~¨Ó¦³´X®a¬Û¦PÃĪ«1´Á¸Ñª¼«á³£¤jº¦5¦¨~1¿¥H¤W,¦ý¥u¦³¨È·à±d¦V¤U¶^±¼¤@¥bªÑ»ù¥H¤W, ¦pªG¯uªº¦p³oÓªO¤W¤ÀªRªº¼Æ¾Ú¨º»ò¦n,ªÑ»ù¬°¦óÁÙ¬O«®À??Ãø¹D¬O¨º¨Ç§ë¸ê¾÷ºc¥þ³¡¬Ý¨«²´½M¤F¤£±¤¦¨¥»¤@¸ô¨g½æ? ¨Æ¹ê¬O¨È·à±dªº¼Æ¾Ú´N¬O®t©ó¹w´Á,¤§«á¤]¤£·|¦³±Ë»ò¤H·|¨Ó½Í±ÂÅv©Î¬O¨ÖÁÊ,ªÑ»ù±N·|½L¶^¨ì1¶ô¿ú¥H¤U....
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/10/6 ¤W¤È 08:53:03²Ä 4663 ½g¦^À³ ¥H¤U¬O 9/29 ªº¬Ýªk ¦Ü¤µ¤£ÅÜ
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/9/29 ¤W¤È 09:06:30²Ä 4559 ½g¦^À³ ¬Û«H¶R¨È·à±dªº¦U¦ì¤j¤j,¥¼¶}¼ú¤§«e³£¦bÀqÀq½Lºâ,§Úªº¦Ê¸U§ë¸ê¦b¤E¤ë¸Ñª¼«á·|½¦¨¦n´X¿·Ç³Æ¶R¨®¶R©Ð¤F,¦ý³o¦¸¶}¼úµ²ªG´N¬O¤£¦p¹w´Á,§Ú¥i¥H§i¶D¦U¦ì°ê¥~¦U§ë¸ê¶R®a¹Î¶¤¬O¤£¶R³æªº,¤]¤£n¬Û«H±Ë»ò§ë¸ê¾÷ºcµ¹¥Ø¼Ð»ù8¶ô¿ú(³o¨Ç³£¬O½æªÅªº¦nªB¤Í,§Aªº¿ú³£¬O³Q³o¨Ç½æªÅªÌÁȨ«)! °ê¥~ªº§ë¸ê¹Î¶¤¤£¬Oªxªx¤§½ú,I«á¬ã¨s¹Î¶¤ªº¥\¤O¤£ª¾¹D±j¹L³oÓª©ªº¬Y¨Ç¤ÀªR¼Æ¦Ê¿!¤]¤£·|¸ò§AºtÀ¸..¦n¼Æ¾Ú´N¬O¤j¶R,Äê¼Æ¾Ú´N¬O¤j½æ! ¦pªG¯uªº¹Ú¿ô¤F´NÅý¥L¿ô§a,¤d¸U¤£n¨I¾K¦b¹Ú¸Ìn¶}©l¾Ç·|±¹ï²{¹ê ! ¬üªÑºD©Ê¦pªG¤j¶^«áªº¹j¤ÑÁÙ¬O¤j¶^,¤§«áªº¼Æ©P±N·|«ù³Ð·s§C,¤£«H¶Ü ?11¤ë1¤é¤j®a¨ÓÅçÃÒ ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2022/2/24 ¤U¤È 04:47:10
²Ä 5144 ½g¦^À³
|
To:³¯¤j
À³¸Ó¤£¬O¬Æ»ò«nªº¦n®ø®§¡A¤£µM¦´N¤Wº¦¤ÏÀ³¤F~~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/2/23 ¤U¤È 10:24:46
²Ä 5143 ½g¦^À³
|
§Úª¾¹D¤½¥q¦¤w°±¤îaslan001ªº¬ã¨s
¬°¦ó2022.2.22ÁÙ¦³³o¤å³¹µoªí
Aslan completes gastric cancer trial Aslan Pharmaceuticals¡¦ ASLAN001 (varlitinib) had its Likelihood of Approval (LoA) rise in gastric cancer after the completion of a Phase II/III trial. The candidate¡¦s LoA increased by seven points to 56%.
GlobalData¡¦s review happened on 16 February following the ClinicalTrials.gov update on 15 February. LoA is identified via GlobalData¡¦s analysis using a combination of machine learning and its proprietary algorithm.
The Phase II/III study (NCT03130790) enrolled 52 patients with first-line advanced or metastatic gastric cancer. Patients received the chemotherapy cocktail modified FOLFOX6 with either varlitinib or placebo. The trial has two coprimary endpoints investigating tumour size at week 12 at the trial¡¦s phase II portion, and overall survival at the phase III portion. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/2/23 ¤U¤È 10:13:04
²Ä 5142 ½g¦^À³
|
¨º¬O56¤Hªº2´Á¡A¥»p¹º¤T´ÁGÀù350¤H¨SÄ~Äò°µ¡C
¤½¥q¤x¤¤¤îASLAN001 ªº¶}µo¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/2/23 ¤U¤È 09:26:59
²Ä 5141 ½g¦^À³
|
¤Ñ©R¤j¯à¤ÀªR¤@¤U¡A¬O§_Aslan001GÀù¤S¦³·s¶i«×¶Üwww.clinicaltrialsarena.com/analysis/pipeline-moves-aslans-shot-at-approval-jumps-in-gastric-cancer-after-phase-ii-iii-completion/ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2022/2/23 ¤U¤È 05:56:45
²Ä 5140 ½g¦^À³
|
«ö·Ó³W©w¡A¥ô¦ó¤@®a¯Ç´µ¹F§J¤W¥«¤½¥q¦pªG¦b³sÄò30Ó¥æ©ö¤é¤º¡AªÑ»ù§C©ó1¬ü¤¸¡A±N·|¦¬¨ì¨Ó¦Û¯Ç´µ¹F§J°lÂܳo®a¤½¥qªº³ø§i¡Aµ¹¤©¬°´Á90¤ÑªºÄµ§i¡F¸Ó¤½¥q¥²¶·¦Û¤v®³¥X¤@®M¬@±Ïp¹º¨Ó®¾¦^ÀZ¶Õ¡C
¦pªG¸Ó¤½¥q¦b90¤Ñĵ§i´Á¤º¤´ÂµLªk§ïÅܲ{ª¬¡A¤]´N¬O¡GµLªk¦b³o¬q´Á¶¡¦³³sÄò10Ó¥æ©ö¤é¨ÏªÑ»ùªð¦^¨ì1¬ü¤¸¥H¤W¡A³o®a¤½¥q´N·|³QºKµP¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2022/2/23 ¤U¤È 05:16:12
²Ä 5139 ½g¦^À³
|
¤j®anª`·N~·íªÑ»ù³sÄò30¤Ñ¤p©ó1¬üª÷®É~¤½¥qÀ³¸Ó´N·|±µ¦¬¨ìNASDAQ¤½§i180¤Ñ¤º´£¥X§ïµ½pµe!¦pªG¨S¦³´£¥X§ïµ½pµe®£¦³¤U¥«·ÀI !! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2022/2/23 ¤U¤È 12:57:09
²Ä 5138 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/2/23 ¤U¤È 12:26:10
²Ä 5137 ½g¦^À³
|
³¯¤j¡A «Øij±z¡A MOA¡H ©MDupilumab¦³¦ó®t²§¡H Ävª§¤O¡H
¥H¤W¥ý¬ã¨s²M·¡¡I
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/2/23 ¤U¤È 12:10:17
²Ä 5136 ½g¦^À³
|
¤Ñ©R¤j §A¤@ª½±j½Õ004ªºMOA¤w½T»{¡AÃÄÃÒÀ³µL°ÝÃD
³o¨ä¤¤¬O§_¦³¥i¯à¡Aµo¥Í¦³¤H¤W¤U¨ä¤â¤H¿Ñ¤£»Nªº¥i¯à©Ê¡H
¨Ì§A©Ò¨£¦Ñ·àªº¥¼¨Ó¡A©|¦³¥i¬°¶Ü ÁÙ¬O¤@¤ÁÅ¥¤Ñ¥Ñ©R
·PÁÂ
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/2/23 ¤W¤È 10:23:30
²Ä 5135 ½g¦^À³
|
§Ú«DÂå¾Ç¥»¬ì¨t¡A¥Lª©¤£´±³y¦¸¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2022/2/23 ¤W¤È 08:35:17
²Ä 5134 ½g¦^À³
|
¤Ñ©R¤j¡A«ôŪ¦h½g±zªº¤å³¹¡A¦³¤@§x´b·Q°Ý¡A ¥H±z²W³Õªº±M·~ª¾ÃÑ¡A¦ó¥H¿WÁé¨È·à¡H ¨ä¥¦¹³¯E¹©¡B¦X¤@¡B¥_·¥¬P⋯¬°¦ó¤£¦b±zÃö·Rªº²´¯«¡H
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/2/22 ¤U¤È 09:57:23
²Ä 5133 ½g¦^À³
|
2/22¯E¹©«Å¥¬¡A»P±dÄ˯E¿Õ¡]»´ä¡^¤½¥q¤wñ¸p±MÄݱÂÅv¨óij...¦Xp³Ì°ª¥i¹F¬üª÷2»õ¤¸¡C
¤j³°¦û¥þ²y¸~½FÃÄ¥«³õ¬ù11%.
2/11%==18»õ¬ü¤¸¾P°â---(¥þ²y¾P°â¹w´ú) 3*18=54»õ¬ü¤¸¥i¯à¥«È-----(¦b¬ü°êÃÄ«~¤W¥«¤TӤ뤺¥i¯àªº¥«È)
OBI999 ,¤G´Á¦¨¥\,´N·Ç³Æ¥Ó½Ð¬ü°êÃĵý.(¥|´ÁÀùµý----¥i¯à3½u«áªº¥ÎÃÄ),¦P®É°µ¤T´Á.
¥«³õ·|¦p¦ó¶]?¤£ª¾!
¯E¹©·sÃıÂÅv¤¤´ä¿D ñ¬ùª÷¥[¨½µ{¸Oª÷³Ì°ª2»õ¬ü¤¸ ¤¤¥¡ªÀ°OªÌÁú´@´@¥x¥_22¤é¹q (2022-02-22 20:25:01) ¥xÆW¯E¹©¥Í§Þ«Å¥¬¡A»P±dÄ˯E¿Õ¡]»´ä¡^¤½¥qñ¸p¨óij¡Aµ¹¤©¯E¹©ºX¤U¥D°Ê§K¬Ì§ÜÀù·sÃÄOBI-833¤Î§ÜÅé¤p¤À¤lÃĪ«½Æ¦XÅéOBI-999¦b¤¤°ê¦a°Ï¡]§t»´ä¡B¿Dªù¡^ªº±MÄݱÂÅv¡C
¯E¹©ªí¥Ü¡A¨Ì¾Úñ¸pªº¨óij¡A±ÂÅv±ø¥ó¥]§tñ¬ùª÷¡B¨½µ{¸Oª÷µ¥¡A¦Xp³Ì°ª¥i¹F2»õ¬ü¤¸¡A¨ä¤¤Ã±¬ùª÷¬°1200¸U¬ü¤¸¡A¨Ì¾P°â²bÃB©â¦¨ªº¾P°âÅv§Qª÷¡A¨ä¦Ê¤À¤ñ³Ì°ª¥i¹F2¦ì¼Æ¡F¥B¥ÑOdeon t³d¨â¶µ·sÃĦb¤¤°ê¡B´ä¿D©Ò¦³¶}µo¦¨¥»¤ÎÀH«áªk³Wµn°O©M°Ó·~¤Æ¦¨¥»¤ä¥X
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2022/2/21 ¤U¤È 08:18:11
²Ä 5132 ½g¦^À³
|
¤@¤Á³£¬O¦]½t¡A ±o¦AÅ¥´¼¼z¤§¨¥¡ã |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2022/2/21 ¤U¤È 01:42:25
²Ä 5131 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/2/19 ¤W¤È 09:37:52
²Ä 5130 ½g¦^À³
|
¦nÁà°_©ó¤ß¤½®×
ðsÆ[¤¤¥|¯ª¹D«HÁI®v»»Æ[®ð¶H¡Aª¾¤ûÀY¤s¦³©_²§¤§¤H¡A¤D°`¦Û´M³X¡C¤J¤s«á¨£ªk¿Ä®vºÝ§¤¦ÛY¡A´¿µL©ÒÅU¡C
(½t°_©ó²{¶H¬É¡A¥|¯ªµ½Æ[²§¶H¡A±oª¾¤ûÀY¤s¦³²§¤H¡A¤D¤J¤s¤@±´¨s³º¡C¨£¤HºÙªk¿Ä¦æªÌ¡AºÝ§¤Æ[¤ß¡A¤£²z¤£¸B³X«È¡A¯u¬O¦Û¦bµLê¡C)
¥|¯ª°Ý¤ê¡G¡u¦b¦¹§@¤°»ò¡H¡v
(¤j¼wºÝ§¤©ó¦¹¡A¤£ª¾¦ó¬°«v¡I)
®v¤ê¡G¡uÆ[¤ß¡I¡v
(ªk¿Ä®vµª»¡¡A¦b¦¹ÁI§¤Æ[¤ß¡A§V¤O¥Î¥\½Õ¤ß¡C)
¥|¯ª¤ê¡G¡uÆ[¬O¦ó¤H¡A¤ß¬O¦óª«¡H¡v
(¥|¯ª»¡¯àÆ[ªº¬O½Ö¡H©ÒÆ[ªº¤ß¤S¬O¦óª«¡H)
®vµL¹ï¡A¤Ö³\¡A½Ð¥|¯ª»¡¯uªkn¡C
(ªk¿Ä®v»¡¤£¥X©Ò¥HµM¨Ó¡Aª¾¨Ó¦¹ªÌ¥²¬O°ª¤H¡C«áª¾¬O¥|¯ª¡A¤D½Ð¨ä»¡µL¤W¤ßªkªkn¡C)
¥|¯ª»¡ªkn¤w¡A§Y¤ê¡G¡u¦¼¦ý¥ô¤ß¦Û¦b¡A²ö§@Æ[¦æ¡C¡v
(nÅý¦Û¤ß¦¨¬°¦ò¤ß¡A·í¥ô¨ä¦Û¦bµLê¡A¤£¥Î¯S§OÀ£§í¥¦¡A¤ß°_¤ß·À³£¬O½t°_¤§ªk¡A¤ßÀH¨ä½t¦Ó¥Í·À¡A¤£¥Î¯S·N¥hÆ[¥¦¡A§ó¤£¯àÀ£§í¦Û¤ß¡A¦p¬O¦Ó¤w¡C)
®v¤ê¡G¡u¬J¤£³\§@Æ[¦æ¡A©ó¹Ò°_®É¦p¦ó¹ïªv¡H¡v
(ªk¿Ä®v»¡¡A¬JµM¤£¤¹³\°µÆ[¤ß¤§ªk¡A¨º¤º¤ß¹Ò°_®É¡An¦p¦ó¨Ó¹ïªv©O¡H¯u¬O¥@¶¡ÁI¦æªÌצ檺©T¦³¼Ò¦¡¡AYµLµ½ª¾ÃѱоɡA¯u·|ªP¨«¦Ó¤Jª[³~¨o¡I)
¥|¯ª¤ê¡G
¡u¹Ò½tµL¦nÁà¡A¦nÁà°_©ó¤ß¡A ¤ßY¤£±j¦W¡A¦k±¡¬J¤£°_¡A ¯u¤ß¥ô¹Mª¾¡C¦¼¦ýÀH¤ß¦Û¦b¡A µL´_¹ïªv¡A§Y¦W±`¦íªk¨¡AµL¦³ÅÜ©ö¡C¡v
(¦æªÌY¨Ì¦]½t°_ªk¡A¹ï¹ÒÁÙ¦³¬üÁध©À¡A©w¬O¤º¤ßÁÙ¦³²ß®ð¡B¤ò¯f¦b¡C ¤ßY¤]¯à¤£±j¦w¦W¬Ûµ¹¥ô¦ó¤@ӹҬɡA«h¦¹¦æªÌ¦k±¡¤£°_¡A ½Ñªk¥µ¥©Ê§Y±o¡A¶¶°f¡Bµ½´c¡B¬üÁà¤@¦p¡C ¦æªÌY¤]¯à¦p¦¹¡A«h¯u¤ß¹MÀ³¤@¤Á½t¡AÀ³½tª¾«á¯à¦Û¦bµLê¡A
¦p¦¹·í¤£¥Î¹ïªv¥ô¦ó¹Ò¬É¡C¦æªÌ®©±o¦¹ºØ¹D²z¡A
§Y¦WÀò±oªk¨±`¦í¡Aªk¨ªÅµLÁöÀ³¤@¤Á½t¡A ¦ý¯u¦pµL¦³µ·²@¦aÅÜ©ö¡C) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/2/19 ¤W¤È 09:20:53
²Ä 5129 ½g¦^À³
|
ÁI©v¥|¯ª¡G
¡u¹Ò½tµL¦nÁà¡A¦nÁà°_©ó¤ß¡A ¤ßY¤£±j¦W¡A¦k±¡¬J¤£°_¡A ¯u¤ß¥ô¹Mª¾¡C¦¼¦ýÀH¤ß¦Û¦b¡A µL´_¹ïªv¡A§Y¦W±`¦íªk¨¡AµL¦³ÅÜ©ö¡C¡v
¥Õ¸Ü:
¦æªÌY¨Ì¦]½t°_ªk¡A¹ï¹ÒÁÙ¦³¬üÁध©À¡A©w¬O¤º¤ßÁÙ¦³²ß®ð¡B¤ò¯f¦b¡C ¤ßY¤]¯à¤£±j¦w¦W¬Ûµ¹¥ô¦ó¤@ӹҬɡA«h¦¹¦æªÌ¦k±¡¤£°_¡A ½Ñªk¥µ¥©Ê§Y±o¡A¶¶°f¡Bµ½´c¡B¬üÁà¤@¦p¡C ¦æªÌY¤]¯à¦p¦¹¡A«h¯u¤ß¹MÀ³¤@¤Á½t¡AÀ³½tª¾«á¯à¦Û¦bµLê¡A
¦p¦¹·í¤£¥Î¹ïªv¥ô¦ó¹Ò¬É¡C¦æªÌ®©±o¦¹ºØ¹D²z¡A
§Y¦WÀò±oªk¨±`¦í¡Aªk¨ªÅµLÁöÀ³¤@¤Á½t¡A ¦ý¯u¦pµL¦³µ·²@¦aÅÜ©ö¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/2/19 ¤W¤È 08:43:15
²Ä 5128 ½g¦^À³
|
½Ñ¦æµL±`¬O¥Í·Àªk¡C
¥Í·À·À¤w±I·À¬°¼Ö¡I
¦ò»¡§ë¸ê¡A§Y«D§ë¸ê¡A¬O¦W§ë¸ê¡C
§ë¸ê¥»µL¦Û©Ê¡A¤£¦í©ó¤ß¡A§Y¤J±I·À¤§¹D¡I
¦ó¨ä¦Û©Ê¥»¦Û¨ã¨¬¡I ¦ó¨ä¦Û©Ê¥»¤£¥Í·À¡I ¦ó¨ä¦Û©Ê¥»¤£°Ê·n¡I ¦ó¨ä¦Û©Ê¯à¥Í¸Uªk¡I
µÐ´£¥»µL¾ð¡A©úÃè¥ç«D¥x¡A ¥»¨ÓµL¤@ª«¡A¦ó³B·S¹Ð®J¡I <¤»¯ª>
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2022/2/18 ¤U¤È 11:19:36
²Ä 5127 ½g¦^À³
|
¤Ñ©R¤j §ë¸ê¬O§_Àò§Q¹B®ð¦û¤ñÁÙÆZ¤jªº¡A´N¦p¦P¶R¤@´É©Ð¤l¡Aµ¡Ã®£¸©Ô¶}´N¯à¬Ý¨ì¥Rº¡´Â®ð»P§Æ±æ ªº´º½o¡A´Á³\¶}±Ò¨º®°µ¡¤~¬O«ÂI¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/2/18 ¤W¤È 07:18:56
²Ä 5126 ½g¦^À³
|
¥xÁÞ¤j¡A
¨È·à±d¥Lª©¬O¦s资®Æ¡A¥»ª©¬Ò¦³©ñ¡C
¥u¯d2ª©¡A资°TÃø¬d¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2022/2/17 ¤U¤È 11:02:47
²Ä 5125 ½g¦^À³
|
¤Ñ©R¤j ¥²´Iºô¨È·à±d°Q½×°Ï¤Ñ©R¤jÁ`¦@¶}¤F¤Q¤@Óª©¡A«Øij«¶}¨Ãºë²¦¨Aslan004»PAslan003¨âÓª©¡A§â¥H«e«nªº¼Æ¾Ú¸ê°T«¶K¹L¨Ó¡A´£¨Ñª©¤Í°Q½×¡A¤£½×¤°»ò¤º®e³£¥i¤À¨É¡A·s¦~·s®ð¶H·sª©±¡A¨È·à±d¥Ø«e¬ãµoªº¬O¤jÃĤ£¬OÁx¹DÀùªº©t¨àÃÄ¡C
¨È·à±d004ªºÁ{§É¹êÅç³]p¥l¶Ò±Æ°£±ø¥ó¦³´£¨ì¥´¤°»ò¬Ì]¤£¯à¦¬¤J¡A¨ä¥L¬Ì]¤£·|¦³¼vÅT¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/2/17 ¤U¤È 01:20:32
²Ä 5124 ½g¦^À³
|
«Øij¥h§ä dupilumab ªº·sÁ{§É¸ê¨³,¬Ý¦³µL¨ü¼vÅT? ¤j®aÀô¹Ò¬Ò¤@¼Ë! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2022/2/17 ¤W¤È 10:55:17
²Ä 5123 ½g¦^À³
|
¦U¦ì¤j¤j,·s¦~¦n :
·Q»P¤j®a°Q½×¤@Ó°ÝÃD,¥Ø«e¨È·à004-2B¦b¬ü°ê¦¬®×, ¦ý·s«a¬Ì±¡¨ÏµM,¦³¥i¯à¥Ø«e¦¬®×¯f±w¦P®É¤]¥i¯à±µ¨ü²Ä¤G©Î²Ä¤T¾¯¶qªº·s«a¬Ì],P¨ÏÅ餺¤¤©M§ÜÅé¿@«×°¾°ª, ¦p¦¹ª¬ªp¤U,¦³¥i¯àª½¶¡±µ³y¦¨004ÃĮĨü¨ì¼vÅT¶Ü ?
Åwªï¤j®a´£¨ÑÄ_¶Q·N¨£~~~~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2022/2/16 ¤W¤È 11:53:05
²Ä 5122 ½g¦^À³
|
www.hcplive.com/view/laboratory-markers-aid-in-evaluating-atopic-dermatitis |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2022/2/16 ¤W¤È 09:13:45
²Ä 5121 ½g¦^À³
|
¦X¤@ªk»¡¸ê®Æ¡G FB825¸ò¨ä¥DnÄvª§¹ï¤âÁɿյ᪺dupixent¤ñ¸û¡C
ÁÉ¿Õµá¦b2020¦~¾P°â35»õ¬ü¤¸¡A¹w¦ô¦b2028¥«³õªº¾P°âȬO100»õ¼Ú¤¸¡C
FB825¤@Ó¤ë¥un¥´¤@¾¯¡AµLÄY«°Æ§@¥Î¡Fdupixent¤@Ó¤ë¬On¥´¤G¦¸¡A¥BÁÙ¦³°Æ§@¥Î |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/2/15 ¤U¤È 10:36:36
²Ä 5120 ½g¦^À³
|
whalewisdom.com/stock/asln
2021/Q4 ªÑÅvÅÜ°Ê
°ô´î«e¤G¦W
SILVERARC CAPITAL MANAGEMENT, LLC ¼W«ù1,498,192 ADRªÑ TANG CAPITAL MANAGEMENT LLC ¼W«ù1,079,620 ,²Öp«ùªÑ2,054,925 ADRªÑ
IKARIAN CAPITAL, LLC ´î«ù500,000 ADRªÑ POINT72 ASSET MANAGEMENT, L.P. ´î«ù250,000ADRªÑ 2
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2022/2/11 ¤U¤È 08:41:29
²Ä 5119 ½g¦^À³
|
´N§Ú¹ïÄw½XªºÆ[¹î ·à¤lÀ³¸Ó¯àºCºC¦uÃ1¤¸½w¨B¦V¤W ¤§«e©ß°âªº½æÀ£À³¸Ó®t¤£¦h¤F 1¤¸¥H¤U¶q´N·|Åܱo«Ü¤p¡A¨S¤°»ò¤H·Q½æ ²{¦b´NºCºCµ¥004ªº¹êÅç¼Æ¾Úµo»Ã§a |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/2/11 ¤U¤È 05:05:09
²Ä 5118 ½g¦^À³
|
¤µ(2022)¦~¥þ²y¤Q¤jºZ¾PÃĪ« Dupilumab±N·|À½¶i¥þ²y«e¤Q¤j ©¡®É¼Ðº]Àø®Äµ¥³£Ä¹¹LDupilumabªºASLAN004 ±N·|¤Þ°_¨ÖÁÊÃļtªºÁ»¿Ì. (2022¦~11¤ë±q¦U¤jÃļtQ3°]³ø´Nª¾¹D¥þ²y¤Q¤jºZ¾PÃĪ«±Æ¦W¤F) ¨È·à±d®É¶¡ÂIºâ±oèè¦n.¼F®`. 1.2022¦~Q4´Á¤¤³ø§i 2.2022¦~11¤ë¤½¥¬2022¦~¥þ²y¤Q¤jºZ¾PÃĪ«¹w´ú(Dupilumab±N¥X¦C) 3.2023¦~Q1±ÂÅv 4.2023¦~Q1_ASLAN004¥¿¦V¸Ñª¼ 5.µ¥³Q¦¬ÁÊ
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/2/11 ¤W¤È 09:20:19
²Ä 5117 ½g¦^À³
|
Dupixent 2021¦~À禬62»õ¬ü¤¸
¼s§i费 4»õ¬ü¤¸
4/60=1/15 =6.7%
¬Û·í©ó°µ¤@ÓAD¤T´ÁÁ{§É费¥Î¡C
¦ô 2022¦~À禬 82»õ¬ü¤¸¥H¤W 2023¦~À禬(¤W¥«²Ä¤C¦~) ±N¯}¦Ê»õ¬ü¤¸ Âà¶K û¡GROGER588910148151 µoªí®É¶¡:2022/2/11 ¤W¤È 07:59:50²Ä 1686 ½g¦^À³ 2020«e10¤jÂåÃÄ[¼s§i¶O]±Æ¦æ www.biotechdistrict.com/post/top-pharmaceutical-ad-spenders-of-2020
1:Humira (¤£·\¬O¦~¾P°âÃB¯}200»õ¬ü¤¸ªºÃĤý¡A¼s§i¶O¤]«ÜÅå¤H) 2020¦~:4.9985»õ¬ü¤¸/2019¦~:5.773»õ¬ü¤¸
2:Dupixent(ý³Ý»P¥Ö½§ª¢¡A³o¤ä¦b[¼s§i¶O¥Î]»P[¾P°âÃB]¼Wªø³t²v¦Pµ¥Åå¤H) 2020¦~:4.098»õ¬ü¤¸ /2019¦~:1.994»õ¬ü¤¸
10:Otezla(2020¦~¾P°âÃB22»õ¬ü¤¸)2020¦~:1.504»õ¬ü¤¸ /2019¦~:1.559»õ¬ü¤¸ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2022/2/5 ¤U¤È 11:27:45
²Ä 5116 ½g¦^À³
|
³o¤ºØ¯e¯f¥]¬A ºC©Ê¦Ûµo©ÊëC³Â¯l¡]CSU¡^ ¶Ý»Ä©Ê¹ºÞª¢¡]EoE¡^ ²§¦ì©Ê¥Ö½§ª¢ AD ý³ÝAsthma ¦ñ¦³»ó®§¦×¯fªººC©Ê»óÄuª¢¡]CRSwNP¡^¡C
¸Ó¼Æ¾Úªº¸Ô²Ó«H®§¨Ó¦Û 18 ½gºKn¡A§¡ªí©ú Dupixent §í¨îªº IL-4 ©M IL-3 ³~®|¬O¤Wz¯e¯fªº¼ç¦b°^ÄmªÌ¡A±q¦Ó¼W¥[¤F¤ä«ù³o¨Ç¾AÀ³¯gªº¤u§@¡C ¨â¶µ III ´Á¬ã¨sªº³Ì·sµo²{¤]¬ð¥X¤F¸ÓÃĪ«¹ï§Üµ²¸`©ÊÄo¯lªº¼ç¤O¡C
§ó¦h«H®§±N¦b¤½¥q©ó 2 ¤ë 25 ¤é¦Ü 28 ¤é¦b¬ü°ê¹L±Ó¡Bý³Ý©M§K¬Ì¾Ç·|¦~·|¤WµoªíªººtÁ¿¤¤¤½§G¡C
ASLAN004 ªv¯f¾÷¨î»PDupilumab¬Û¦P¡A¤S¦h¥X¤TºØ¾AÀ³¯g¡A¤]ºâ¬O§Q¦h¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2022/2/5 ¤U¤È 03:34:12
²Ä 5115 ½g¦^À³
|
www.biospace.com/article/regeneron-sanofi-score-more-wins-for-dupixent-across-five-indications/ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/2/5 ¤U¤È 12:42:45
²Ä 5114 ½g¦^À³
|
Dupilumab 2022¦~¬ü°ê¥Ø¼Ð¥«³õº¯³z²v¦ô¶È4.7%
--------------------------------
2021¦~¬ü°Ï¾P°â47.12»õ¬ü¤¸.
Dupilumab 3000*12*.8=28,800 ¬ü¤¸/¦~¾P
47.12»õ¬ü¤¸/2.88¸U¬ü¤¸=16.36 ¸U-¦~
16.36/346.5=4.7% (2022¥ó¤w¤W¾AÀ³µý¥«¥Ø¼Ð¥«(³õ)=346.5¸U¤H)
2023¦~¦ô¥i¨úDupilumab·sÃĵý,¦p¤U
Eosinophilic Esophagitis (EOE), ¬ü¥Ø¼Ð¥«³õ48K
Chronic Spontaneous Urticaria(CSU),¬ü¥Ø¼Ð¥«³õ308K_
Prurigo Nodularis(PN),¬ü¥Ø¼Ð¥«³õ74K
¤pp 430K(¥¼¨ü±±,¬ü°ê¥Íª«»s¾¯¼ç¦b¥«³õ)
2022¦~©³«e,¤w¨úDupilumabÃĵý,¦p¤U
1.AD 2300K 2.Asthma 975K 3.CRSwNP 90K
¤pp 3465K(3,465,000¤H)(¥¼¨ü±±,¬ü°ê--¥Íª«»s¾¯¼ç¦b¥«³õ)
Dupilumab 2021/Q4°]³ø¥XÄl investor.regeneron.com/static-files/2312afdd-0a3e-47cd-a8ed-d0ad3d9a83ad Q4³æ©u½æ17.74»õ¬ü¤¸,2021¦~²Öp¦ÜQ4 ¾P°â62»õ¬ü¤¸ Dupixent /Dupilumab ³æ¦ì:¦Ê¸U¬ü¤¸ USA(¬ü°ê)// ROW (¨ä¥L°Ï°ì)//¤pp
2021 Q1 961.5 //301.4//1262.9 Q2 1140//352//1492 Q3 1256.7//406.2//1662.9 Q4 1348//426//1774 ¦Xp 4712.8//1486//6198.8 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/2/5 ¤W¤È 11:59:19
²Ä 5113 ½g¦^À³
|
Dupilumab 2021/Q4°]³ø¥XÄl investor.regeneron.com/static-files/2312afdd-0a3e-47cd-a8ed-d0ad3d9a83ad Q4³æ©u½æ16.63»õ¬ü¤¸,2021¦~²Öp¦ÜQ4 ¾P°â62»õ¬ü¤¸
2020¦~¥þ¦~¾P°â½æ40.4»õ¬ü¤¸¡C2021¦~¦~¦¨ªø53%
¦ôp2022¦~¥þ²y¾P°â 82~85 »õ¬ü¤¸ -------------------------------------- Dupixent /Dupilumab ³æ¦ì:¦Ê¸U¬ü¤¸ USA(¬ü°ê)// ROW (¨ä¥L°Ï°ì)//¤pp
2021 Q1 961.5 //301.4//1262.9 Q2 1140//352//1492 Q3 1256.7//406.2//1662.9 Q4 1348//426//1774 ¦Xp 4712.8//1486//6198.8
2020 Q1 679.0 174.2 853.2 Q2 770.4 176.6 947.0 Q3 851.2 221.4 1072.6 Q4 925.6 246.4 1172.0 ¤pp3226.2 818.6 4044.8
2019 Q1 303.0 70.7 373.7 Q2 454.7 102.6 557.3 Q3 508.3 124.8 633.1 Q4 605.2 146.3 751.5 ¤pp 1,871.2 444.4 2,315.6
2018 Q1 117.2 14.2 131.4 Q2 180.9 28.3 209.2 Q3 219.6 43.0 262.6 Q4 258.6 60.2 318.8 ¤pp 776.3 145.7 922.0
2017 Q1 ******* Q2 ******* Q3 88.5 0.5 89.0 Q4 136.9 2.0 138.9 ¤pp 225.4 2.5 227.9 2017/03/28 FDA®Öã¤W¥« |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2022/2/3 ¤U¤È 11:04:07
²Ä 5112 ½g¦^À³
|
©t¨àÃĤj ì¼ÐÃD¥D¤å Y2022¦~¤¤±N¨È·à±dªº¥«È±a¤W10»õ¬üª÷¡A±z´N¬O¨ô¶VªºCEO ¤£n¥Î±z´N¬O...
«Øij§ó§ï¦¨ Y2022¦~¤½¥q¯à±N¨È·à±dªºÁ`¥«ÈÂX¼W¹F10»õ¬ü¤¸¥H¤W¡ACarl Firth±N¦¨¬°£¸¦ì«D±`¨ô¶VªºCEO
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/27 ¤W¤È 04:52:19
²Ä 5111 ½g¦^À³
|
×¥¿ www.worldometers.info/coronavirus/usa/florida/
¬ü°ê¦ò¬w
1.2021¦~8¤ë13¤é·P¬V 25,730¤H -.2021/08/28---°ª峄 ¦º¤` 426¤H
¦º¤`²v426/25730=1.65%-----a
2.2022¦~¤¸¤ë12 ¤é·P¬V 76,769¤H ---2020¤¸12--°ª峄¦º¤` 80¤H 80/76769=0.104%-----b
b/a=8%-------Omicorn ¦º¤`²v·ÀI¤ñ§C¬O4Ó¤ë¬y¦æªº¯f®è Detalªº 8%
3..¬ü°ê´¶³q·P«_¥§¡¦º¤`²v¬ù 0.13%¡C----d
www.cdc.gov/flu/images/about/burden/influenza-burden-chart2-960px.jpg (®Ú¾Ú¬ü°êCDC²Îp¹Ïªí¡A2017-18¦³4500¸U¤H±o¨ì·P«_(14% of 3.4»õ¤H)¡A81¸U¤H¦í°|ªvÀø¡A6¸U1¤d¤H(0.13%)¯f¦º ¡C
4. b/d= 0.104%/0.13%=80% Omicorn ©M©ó¬ü°ê´¶³q·P«_¥§¡¦º¤`²vªº·ÀI¤ñ ¬ù 80% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/26 ¤U¤È 10:57:09
²Ä 5110 ½g¦^À³
|
www.worldometers.info/coronavirus/usa/florida/
¬ü°ê¦ò¬w
1.2021¦~8¤ë13¤é·P¬V 25,730¤H -.2021/08/28---°ª峄 ¦º¤` 426¤H
¦º¤`²v426/25730=1.65%-----a
2.2022¦~¤¸¤ë12 ¤é·P¬V 76,769¤H ---2020¤¸12--°ª峄¦º¤` 80¤H 80/76769=0.0104%-----b
b/a=0.8%-------Omicorn ¦º¤`²v·ÀI¤ñ¶W§C¬O4Ó¤ë¬y¦æªº¯f®è 0.8%
3..¬ü°ê´¶³q·P«_¥§¡¦º¤`²v¬ù 0.13%¡C----d
www.cdc.gov/flu/images/about/burden/influenza-burden-chart2-960px.jpg (®Ú¾Ú¬ü°êCDC²Îp¹Ïªí¡A2017-18¦³4500¸U¤H±o¨ì·P«_(14% of 3.4»õ¤H)¡A81¸U¤H¦í°|ªvÀø¡A6¸U1¤d¤H(0.13%)¯f¦º ¡C)
4. b/d= 0.0104%/0.13%=8% Omicorn ¦º¤`²v·ÀI¤ñ¶W§C¬O¬ü°ê´¶³q·P«_¥§¡¦º¤` ¬ù 8% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/26 ¤U¤È 08:58:56
²Ä 5109 ½g¦^À³
|
³Ì·s§ó§ï2bÁ{§Ép¹º clinicaltrials.gov/ct2/show/NCT05158023?term=Aslan004&draw=2&rank=3
¬ü°ê¦ò¦{¶}©l©Û¶Ò¡C¨È¡B¿D¼È½w¡C
§ï¤²Õ¬I°w¬Ò¬Û¦PªºÀW²v¡C
¤@¡B¦w¼¢¾¯²Õ 0¡A1¡A2¡A4¡A6¡A8¡A10¡A12¡A14 ¶g¦U¤@°w ¤G¡BASLAN004 300mg²Õ¡A¨â¶g¤@°wQ2W 0¡A1¡A2¡A4¡A6¡A8¡A10¡A12¡A14¶g¦U¤@°w¡A¦@9°w¡A2700mg¡]¦Xp¾¯¶q¦PDupilumab¡^ ¤T¡BASLAN004,400mg²Õ¡A¨â¶g¤@°wQ2W 0¡A1¡A2¡]¦w¼¢¾¯¡^¡A4¡A6¡A8¡A10¡A12¡A14¡A¦@8°w¡A3200mg¡KASLAN004 ¥|¡BASLAN004¡A400mg²Õ¡A¥|¶g¤@°w¡AQ4w 0¡A1¡A2¡A6¡A10¡A14,¦@6°w¡A¡K¡KASLAN004¦Xp2400mg 4¡A8¡A12¡A¦@3°w.¡K¦@3°w¡K¡K¡K¦w¼¢¾¯
¤¡BASLAN004¡A600mg²Õ¡A¥|¶g¤@°w¡AQ4w 0¡A1¡A2¡A6¡A10¡A14,¦@6°w¡A¡K¡KASLAN004 ¦Xp3600mg 4¡A8¡A12¡A¦@3°w.¡K¦@3°w¡K¡K¡K¦w¼¢¾¯
¦w¼¢¾¯¤ñ¸û¾¹¡G¦w¼¢¾¯¨C¨â¶g¤@¦¸¡]Q2W¡^ ¦w¼¢¾¯Q2W - ¦w¼¢¾¯¥[¸ü°ò½u©M²Ä1¶gªº¾¯¶qµ¥¦Pª«¡AµM«á¨C2¶g¡]Q2W¡^±q²Ä2©P¨ì²Ä14¶gªº¨C2¶g¡]Q2W¡^¦w¼¢¾¯¾¯¶qµ¥¦Pª«¡C ÃĪ«¡G¦w¼¢¾¯ ¥Ö¤Uª`®gªºµLµß·»²G
¹êÅç¡Gaslan004 300 mg q2w aslan004 300 mg q2w - ¦b°ò½u©M²Ä1¶gªº¸Ë¸ü¾¯¶q¡AµM«á¬O¨C¶g2¦Ü²Ä14¶gªº±`³W¾¯¶q¬°300mg Q2w¡C ¥Íª«¾Ç¡Gaslan004. ¥Ö¤Uª`®gªºµLµß·»²G
¹êÅç¡Gaslan004 400 mg q2w aslan004 400 mg Q4w - ¦b°ò½u¡A²Ä1©P©M²Ä2¶g¥[¸ü¾¯¶q¡A¨ä¦¸¬O±`³W¾¯¶q¬°400 mg aslan004¡A»P¦w¼¢¾¯¾¯¶qµ¥¦Pª«¥æ´À¡A±q²Ä4©P¨ì²Ä14¶gªºQ2W¡C ¥Íª«¾Ç¡Gaslan004. ¥Ö¤Uª`®gªºµLµß·»²G
¹êÅç¡Gaslan004 400 mg¨C¥|©P¡]q4w¡^ aslan004 400 mg Q4w - ¦b°ò½u¡A²Ä1©P©M²Ä2¶g¥[¸ü¾¯¶q¡AµM«á©w´Á¬°400²@§J©Î¥æ´À¦w¼¢¾¯¡]Q2w¡^¦Ü²Ä14¶g¡C ¥Íª«¾Ç¡Gaslan004 ¥Ö¤Uª`®gªºµLµß·»²G ¨ä¥L¦WºÙ¡G¦w¼¢¾¯
¹êÅç¡Gaslan004 600 mg q4w aslan004 600 mg q4w - ¦b°ò½u¡A²Ä1©P©M²Ä2¶g¥[¸ü¾¯¶q¡A¨ä¦¸¬O±`³W¾¯¶q¬°600²@§Jaslan004¡A»P¦w¼¢¾¯¾¯¶qµ¥¦Pª«¥æ´À¡A±q²Ä4©P¨ì²Ä14¶gªºQ2W¡C
Placebo Comparator: Placebo every two weeks (q2w) Placebo q2w - placebo loading dose equivalents at Baseline and Week 1, then placebo dose equivalents every 2 weeks (q2w) from Week 2 to Week 14. Drug: Placebo Sterile solution for subcutaneous injection
Experimental: ASLAN004 300 mg q2w ASLAN004 300 mg q2w - loading doses at Baseline and Week 1, followed by regular doses of 300mg q2w from Week 2 to Week 14. Biological: ASLAN004 Sterile solution for subcutaneous injection
Experimental: ASLAN004 400 mg q2w ASLAN004 400 mg q4w - loading doses at Baseline, Week 1 and Week 2, followed by regular doses of 400 mg ASLAN004, alternating with placebo dose equivalents, q2W from Week 4 to Week 14. Biological: ASLAN004 Sterile solution for subcutaneous injection
Experimental: ASLAN004 400 mg every four weeks (q4w) ASLAN004 400 mg q4w - loading doses at Baseline, Week 1 and Week 2, followed by regular doses of 400 mg or alternating placebo (q2W) to Week 14. Biological: ASLAN004 Sterile solution for subcutaneous injection Other Name: Placebo
Experimental: ASLAN004 600 mg q4w ASLAN004 600 mg q4w - loading doses at Baseline, Week 1 and Week 2, followed by regular doses of 600 mg ASLAN004, alternating with placebo dose equivalents, q2W from Week 4 to Week 14. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/26 ¤U¤È 05:33:28
²Ä 5108 ½g¦^À³
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/1/1 ¤U¤È 02:17:13²Ä 5024 ½g¦^À³ 2.FB825:ÀR¯ßª`®g/1¤ë¤@°w(¦X¤@/LEO):5.3»õ¬üª÷ ---------(²Ä¤@¥NIgE§í¨î¾¯³Ý³ß·ç¼Ö ® á´¹ª`®g¾¯ 150 ²@§J ½Ã¸pµß¬Ì¿é¦r²Ä 000835 ¸¹ Xolair ¶·«öÅ髤ÎIgE°tÃÄ,¥Ø«e¬Oý³Ý³Ì«á¤@½u, AD Á{§É没¦¨¥\)
¥Ñ±ÂÅvª÷®t 5.3»õ¬ü¤¸,¶È°ê»Ú¦æ±¡1/2~1/3,
www1.ndmctsgh.edu.tw/pharm/pic/medinsert/005XOL01.pdf
FB825 2b ¢Ï¢Ò¡ASC §ï¥Ñ¢Ú¢Ó¢Ý °µÅç§É¡A¦ô¤U¥b¦~¶}©l¡C
¦p¦ó³]p? ¤£ª¾
¡X¡X¡X¡X¡X
没¤½¥¬¢Ô¢Ð¢·¢±¢´¡@¢±¢é Á{§É¸Ô²Ó¸ê°T¡AµLªk¤ñ¸û¡I
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/1/26 ¤U¤È 05:00:33
²Ä 5107 ½g¦^À³
|
³Â·Ð¤Ñ©R¤j
¯à§_¤ÀªR¤@¤U¡A¦X¤@FB825»PAslan 004¤§¯S©Ê¡A®Ä¯à»PÀu¯ÊÂI
Åý§Ṳ́F¸Ñ¤@¤U¥¼¨Ó¥i¯àªº¹ï¤â |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/1/26 ¤U¤È 04:33:29
²Ä 5106 ½g¦^À³
|
¦X¤@¤£¯à¿Ä¸ê¨÷¡A¤£ª¾¦p¦ó©ñªÅ
©Î¬O¥t¦³É¨÷¤èªk
©Î¬O·í¤é¨R |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/1/26 ¤U¤È 12:35:52
²Ä 5105 ½g¦^À³
|
¦X¤@ (4743-TW) ºX¤UªvÀø²§¦ì©Ê¥Ö½§ª¢ªº³æ®è§ÜÅé·sÃÄ FB825 ¬ü°ê¤G´ÁÁ{§É¸ÕÅç¡A¤w°õ¦æ³¡¥÷Àø®Ä«ü¼Ð´Á¶¡¤ÀªR¡A¹wp2022¦~¤W¥b¦~§¹¦¨¸ÕÅç¡A¨Ã±N¶i¤J¸Ñª¼¶¥¬q¡C
¦X¤@ªí¥Ü¡A¦¹¸ÕÅç¦@¦¬¯Ç 99 ¦ì¤¤««×²§¦ì©Ê¥Ö½§ª¢±wªÌ¡A¨C¥|¶gµ¹¤©¤@¾¯ FB825¡AªvÀø®Éµ{ 16 ¶g¡B¦@¥|¾¯¡F©e¥ô¬ü°ê CRO(²Ä¤T¤èÁ{§É¸ÕÅç¨ü°U¾÷ºc) ¨Ì¾ÚÁ{§É¸ÕÅç²Îp¤ÀªRpµe (SAP)¡A°õ¦æÀø®Ä«ü¼Æ´Á¶¡¤ÀªR¡A´£¨Ñ°ê»Ú¦X§@¹Ù¦ñ¶i¦æ§PŪ»Pµû¦ô¡C
¦X¤@«ü¥X¡AªvÀø²§¦ì©Ê¥Ö½§¬ü°ê¤G´Á¸ÕÅç«ùÄò¶i¦æ¤¤¡A©Ò¦³Àø®Ä«ü¼Ð¡B¦å²G¥Í¤Æ«ü¼Æ¡BÀËÅé¤ÀªR¡BÃĪ«°Ê¤O¾Ç¡B¦w¥þ©Ê¼Æ¾Úµ¥¡A¹w©w 2022 ¦~¤W¥b¦~¥i§¹¦¨¥þ³¡¸ÕÅç¡A¦P®É¶i¦æ¸Ñª¼¡B½T©w³Ì²×¼Æ¾Ú¤Î¤ÀªR«á¤½§i¸ÕÅçµ²ªG¡C _______________________________________________________________________________________________
¤~¦¬99 ¦ì¤¤««×²§¦ì©Ê¥Ö½§ª¢±wªÌ°µ2´Á ²§¦ì©Ê¥Ö½§ª¢2´Á¸ÕÅ秹¦¨·Ç³Æ¸Ñª¼(111¦~²Ä2©u) §Ú·Ç³Æ©ñªÅ¦X¤@¤F......
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/25 ¤W¤È 06:39:28
²Ä 5104 ½g¦^À³
|
¦ò»¡¤Ñ©R¡A§Y«D¤Ñ©R¡A¬O¦W¤Ñ©R¡I
¤Z©Ò¦³¬Û¬Ò¬Oµê¦k¡A¬Û¬Ò§t©ÊªÅªºÅé©Ê¡A¨£¬Û¤£¦í¬Û¡A§Y¨£¦p¨Óªk¨¦ò¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/1/24 ¤U¤È 11:29:41
²Ä 5103 ½g¦^À³
|
¤Ñ©R¤j
§ÚµL´c·N¡A±¡ºüµo¬ª¡A½Ð®ü²[
Y«D§Aªº¤ÀªR¸Ñ»¡ §Ú¦¤w©ñ±ó |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/24 ¤U¤È 11:21:37
²Ä 5102 ½g¦^À³
|
Y004 2b AD ¸Ñª¼¥¢±Ñ¡A ¥NªíDupilumab Lerbrikiumab/Trolikiumsbªº¤T¤jÃħ@¥Î¾÷Âà(M0A)¤£¥¿½T¡C
¥|¤jÃij̲׬Ҧbªý断«¬II¨üÅé½Æ¦XÅ骺§Î¦¨¡AÀø®Äªí²{¦bªý断¦h¤ÖIL4/IL13 ªº°T®§¶Ç»¼¡C
¤H®adupilumab¥h¦~½æ62-63»õ¸U¬ü¤¸¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/1/24 ¤U¤È 11:16:21
²Ä 5101 ½g¦^À³
|
§Ú±q¨S©Ç§O¤H
¥u©Ç¦Û¤w
§Ú¦p¬OÂå¾Ç±M·~¡A¤£·|¦b¦¹§¾¸Ü |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/24 ¤U¤È 11:04:09
²Ä 5100 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/1/24 ¤U¤È 11:01:02
²Ä 5099 ½g¦^À³
|
2023¦~ªº¸Ñª¼n¶Ò4¤@6»õ¬ü¤¸¡A¤£¦¨¥\¡A¦p¦ó¶Ò¡H
¨ì®É¦p¤£¦¨¥\¡A¥Nªí¤½¥qª±§¹¤F
˳¬¸Ñ´²¡A¦^®a¦Y¦Û¤v |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/24 ¤U¤È 09:42:14
²Ä 5098 ½g¦^À³
|
2023¦~ªº¸Ñª¼n¶Ò4¤@6»õ¬ü¤¸¡A¤£¦¨¥\¡A¦p¦ó¶Ò¡H ¸Ñª¼¥¢±Ñ²v¾÷²v¡AÓ¤H»{¬°Áͪñ©ó¹s¡I
¦]¬°¦Ü¤Ö¥|ÓII2ªºª¢¯gªºMOA¤w¤GÓ¤W¥«¡A¤TÓ¤T´ÁAD¦¨¥\¡A¤@Ó¥¿¦b°µ2bªº004,¦Ó¥Ø«eªº¤T´Á«ü¼Ð¡AEASI75¦pMoA©Ò¥Ü¡A¥iªý¾×Âù¼Ð¹vIL13/IL4ªº°T®§¶Ç»¼¤~¦³lbªºµ²ªG¡A¤]¸ÑÄÀ¬O²Ä¤GÓ¤W¥«Adbry™ (tralokinumab)Àø®Äªº¨â¿¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/24 ¤U¤È 09:15:51
²Ä 5097 ½g¦^À³
|
¥«³õ¬O±M®a¡H
¨º¥«³õ¦b2005¦~«çÅýREGNªÑ»ù¦b10¤¸¡A¥Ø«e600¦h¬ü¤¸¡H
¨ºÓ¬O専®a¡H¨º¤@¤Ñ¬O±M®a¡H ÁÉ¿ÕµáÁÈ60¿¤~¬O±M®a§a¡I
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/1/24 ¤U¤È 09:05:46
²Ä 5096 ½g¦^À³
|
¥u¬O·d¤£À´1b¸Ñª¼¼Æ¾Ú ¸g¤½¥q¦h¦¸»¡©ú¡A¬°¦ó¤´¤£³Q¥«³õ±M®a±µ¨ü¡A ªÑ»ù«ùÄò¤U¶^4Ó¤ë
¦A¤£¤î¶^ ªÑ²¼´X¥G0»ùÈ
½Ö³£¤£¯à«OÃÒ2023¸Ñª¼¤@©w¦¨¥\ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¯T10148959 |
µoªí®É¶¡:2022/1/24 ¤U¤È 08:24:17
²Ä 5095 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2022/1/24 ¤U¤È 04:58:55
²Ä 5094 ½g¦^À³
|
©t¨àÃĤj ª©¤å§ó§ïªº¤£¿ù¡A«Ü¥¿±¡A¨¯W§A¤F¡C 004¤w¶}©l¦¬®×¡A¿D¬w¬Ì±¡½T¶E¤H¼Æ¤U°¤£¤Ö¡A003¼ìºÅ©Êµ²¸zª¢¥«³õ¤j©ó²§¦ì©Ê¥Ö½§ª¢¡A¤W¥b¦~¤]±N¶}©l¦¬®×¡A³o¬O«D±`¦nªº®ø®§¡A¥t¥~Á{§Éªº¶i®i¤½¥qªº¥«ÈÀ³¸Ón¦P¨B´£¤É¡A«Øij¤½¥q°£¤F参¥[°ê»Ú·|ijµoªí¼Æ¾Ú¥~¡A¤]À³µo§G·s»D¡A¥u¦³¦b¤½¥qºô¯¸µo§G¡A°£«D¬OªÑªF¤~·|¥h¬Ý¡A¨ä¥L§ë¸ê¤H¡A§ë¸ê¾÷ºc¥i¯à·|¿ù¥¢³o¨Ç¸ê°T¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2022/1/24 ¤U¤È 03:28:06
²Ä 5093 ½g¦^À³
|
To:ª©¥D
À³ª©¤Ín¨D¥¿¦V¥[«ùªº·§©À¡A³Â·Ð±z§ï¤@¤U¼ÐÃD¦p¤U:
Y2022¦~¤¤±N¨È·à±dªº¥«È±a¤W10»õ¬üª÷¡A±z´N¬O¨ô¶VªºCEO |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/24 ¤U¤È 01:40:36
²Ä 5092 ½g¦^À³
|
¦p¤£¯à¹ý©³¤F¸Ñ004 MOA¤ÎlbÁ{§É¼Æ¾Ú¡A·N¸q ©M Dupilumab¡AAdbry™ (tralokinumab)¡ACIBINQO¤w¤W¥«ªºMOA®t²§¡A°Æ§@¥Î¡C ²Îp¤Wªº·N¸q¡C¤ÎÄvª§¤O
¨º§ë¸ê¤p«¬·sÃĪѷ|«D±`¨¯W¡C ÁÉ¿Õµá2005¦~¶}©l§ë¸êREGN16¦~¡AÀò§Q60¿ 2011¦~11¤ëREGN²Ä¤@ÓÃĤW¥«
Eylea¡]aflibercept¡^¡X¡X-2011¦~11¤ë,FDA®Öã¤W¥«¡ARegeneron Pharmaceuticals(¬ü°ê¾P°â)/«ô¦Õ(¨ä¥L¦a°Ï¾P°â,§Q¼í§¡¤À)
¥Îµu缐ªÑ»ùÁͶաA¬Ý¤£¨ìªø缐¥¼¨Ó¡C
µu缐«ü¼Ð¦óªÌ¡A¦b2005¦~¯à¹w´úREGN 2012¤§«áªº¦æ±¡¡Hµª®×¬O¡C¤£¥i¯à
2014¦~¹w´úREGNªºDupilumab AD¶È¦³¯à½æ¥X7»õ¬ü¤¸¡A 2016¦~2b°µ§¹.ÀòBTD§ï¬°50»õ¬ü¤¸ 2019¦~12¤ë¡AREGN«Å§G¥¼¨Ó100»õ¼Ú¤¸ 2021¦~¥i¾P62-63»õ 2022¦~¡ADupilumab ¥Ø«e¤´µL¼Ä¤â¡C
004¤½¥q«ÅºÙMOA¬ÛªñDupilumab¡A¤wÀò·§©À©ÊÅçµý¦¨¥\¡A¶È¥Î38¤H¡A1b¦b²Îp¤W©úÅã®t²§¡A¡]¦³¾Ç²Îp¾Ç¡A¤~ª¾¦h»ò¤£®e©ö¡^ ©M¹ï·Ó²ÕEASI75¡]¤T´Á«ü¼Ð¡^ITT¤ÀªR50%/13%=380%
¤@¯ëÀù¯gMOAÀø®Ä©M¹ï·Ó²Õ¤ñ¡]HR·ÀI¤ñ¡^150%´N¹LÃö¡A³q±`n300¤Hªº2bÁ{§É¨Óµý©ú¡C
¨º»ò¦nªº004 lb¼Æ¾Ú¡A°Æ§@¥Î§C¡A®³¤£¨ìÃÄÃÒªº¾÷²v±µªñ0¡C
¦]¬°II«¬ª¢¯g¤xMOA¤w¤TÓ¤W¥«¡A¥u¬O¹vÂI¤£¦P¡AÀø®Ä¤£¦P¡A°Æ§@¥Î¤£¦P¡C
¥Ø«e004ªºlbÀø®Ä«ü¼Ð¤Î°Æ§@¥ÎªºÁp¦X»ùȤ´better than Dupilumab¡AÀu©óDupilumab¡C
¤p¤H¤~½¾Ç¼ç¡A¥Ø«e§ä¤£¨ì¤£·|ÀòFDAÃĵýªº¦]¯À¡C
¤@¤@¤@¤@
¬ÝÀ´¼v¤ù¤~¬Oªø§ë°ò¥»¥\, ¡X¡X×¥¿
ASLAN004 MOA -¼v¤ù aslanpharma.com/drug/aslan004/
2.Dupilumab MOA -¼v¤ù
www.dupixenthcp.com/atopicdermatitis/about/mechanism-of-action
MOA www.tsim.org.tw/journal/jour29-6/02.PDF?fbclid=IwAR2B85aLqBUAt5agx6K7u0NkCGTGpr7w6HDCagHhLuu54ZH7FEqHMAdXG3M |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2022/1/24 ¤U¤È 01:10:19
²Ä 5091 ½g¦^À³
|
ª÷¿Ä¥«³õªº²{¹ê±¡A¨ä¹ê¤£¹L¬O¤@´ÚÃÄ¥¢±Ñ¨â¦¸ «ÂI¬O·sÃĶ}µo¤Ó¿N¿ú §ë¸êªÌ¥u¤¹³\¦¨¥\¡A¤£³\¥¢±Ñ ¤£¥Nªí¯à¤O¤£¨¬¡A©Î¥H¤§«eªº¥¢±Ñ ¨Óµû¦ô¥¼¨Óªºª¬ªp |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2022/1/24 ¤U¤È 12:25:42
²Ä 5090 ½g¦^À³
|
¦³¦p¦¹¼ÖÆ[¶Ü
¨È·à±dCEO·d¨º»ò¤[¡A¦³¨º¦¸¦¨¥\¹L
©RÓ¦W´N¥Nªí¤@©w¦¨¥\¶Ü¡A
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2022/1/24 ¤W¤È 10:00:01
²Ä 5089 ½g¦^À³
|
ASLAN004 (Eblasakimab ªì¥XTĪ¡A¦¿´ò¤Wªº·s±¤Õ
³ÌÁA¸Ñª¬ªpªº´N¬O¤½¥qªº®Ö¤ß¤Hª« ¾Ç¦W³£¥X¨Ó¤F¡AÁÙ¯à¬ÝÃa¶Ü¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/23 ¤U¤È 10:49:50
²Ä 5088 ½g¦^À³
|
Âà¶K·|û¡GROGER588910148151 µoªí®É¶¡:2022/1/22 ¤U¤È 04:50:42²Ä 1615 ½g¦^À³ .¤@¤@¤@¤@
2022.1.19 权«Â医学杂§Ó¡m¬húí¤MThe Lancet¡n«½S¡G·s«a¤j¬y¦æ§Y将结§ô (标§Ó时间点¬O2022¦~3¤ë)
news.bioon.com/article/6795119.html 这½g«½S评论¤å³¹ªº§@ªÌ¬O°·±d«ü标ÉO评¦ô¬ã¨s©Ò¡]IHME¡^ªº¥D¥ôChris Murray¡A¥L´N职¤_¦è¶®图华²±顿¤j学¡C¦b过¥h两¦~¤¤¡AMurray团队«ù续为¥Õ宫´£¨Ñ·s«a¬Ì±¡«Ø¼Ò¡A对¯f¦º²vªº预测¤@ª½¤Q¤ÀãÚÌ¡C
¤@¤@¤@¤@
¦³§Q©ó¦¬®×¶i¨B¡A¦ô6¤ë©³¦¬®×§¹¦¨ 10¤ë©³ªvÀø§¹¦¨¡A¥[3Ó¤ë°lÂÜ ¥[¤@Ӥ리100¤¤¤ßªº¸ê®Æ ©ú¦~2/3¤ë¸Ñª¼¡]2023¦~¡^⋯⋯¶Ò¸ê¡þ«D¬ü°Ï±ÂÅv¡]¶Ò¸ê4¡ã6»õ¬ü¤¸ ¤ä¥ICSL¤W´å./¤T´ÁÁ{§É¶O¥Î/3¦~ªºÀç¹B¶O¥Î¡^
2022¦~¤W¥b¦~003IBD ¤G´Áû£°Ê
¸Uªk¬ÒªÅ¡A¤ßµL©Ò¦í¡A¨Æ¨Æª«Ãª |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2022/1/23 ¤U¤È 07:39:58
²Ä 5087 ½g¦^À³
|
¦³¨S¦³¤j¤j¥i¥H¾ã²z¤@¤U ·à¤l´XÓ«nªº®É¶¡ÂI ¨Ò¦p2023¦~004¸Ñª¼(³oÓÁÙ¦n¤[XD) ¨ì®ÉÔ¦A¦^¨Ó¬ÝªÑ»ù´N¦n ¼È®É¥ý§Ñ¤F¥¦§a |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/23 ¤W¤È 08:23:05
²Ä 5086 ½g¦^À³
|
µL©À¬°©v µL¬Û¬°Åé µL¦í¬°¥»
¤»¯ªÁIªk®Ö¤ß
youtu.be/tj2luRdkdj4
10¤ÀÄÁ¥ª¥kªºÁ¿¸Ñ¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/23 ¤W¤È 07:19:22
²Ä 5085 ½g¦^À³
|
¦ò»¡衆¥Í¡A§Y«D²³¥Í¡]²³¥Í©ÊªÅ¡A¨ÃµL¹ê¦bªº²³¥Í¤§¬Û¡^¡A¬O¦W²³¥Í¡]¤è«KºÙ°µ²³¥Í¡^¡I
¦ò»¡¸Uªk¡A§Y«D¸Uªk¡]¸Uªk©ÊªÅ¡A¨ÃµL¹ê¦b¸Uªk¤§¬Û¡^¡A¬O¦W¸Uªk¡]¤è«KºÙ°µ¸Uªk¡^¡I
¦ò»¡Omicron ¡A§Y«DOmicron¡A¬O¦WOmicron¡I
¦ò»¡ªÑ»ù¡A§Y«DªÑ»ù¡A¬O¦WªÑ»ù¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2022/1/22 ¤U¤È 05:23:45
²Ä 5084 ½g¦^À³
|
¥~°ê¤H¤£·|¨Ó³oÃäµoªí¨¥½×(¦Ü¤Ö¤U¥«¨ì²{¦b)¡C ¤ä«ù¦³¼Æ¾Ú²z©Ê¤ÀªRªº¤Ñ©R¤j·íª©¥D©Î¥t¶}ª©°Q½×¡C ¥Ø«e¨S¦æ±¡,©Ò¥H§Ú¦bµ¥²Ä¤T©u: 1.004ªºªº´Á¤¤³ø§i¡C 2.ÁÉ¿Õµá°õ¦æªø½Õ°ª§ùÁת¢2027¦~¹w¦ô¾P°âÃB¡C
|
|
¡@ |
¦^°Q½×°Ï1¶ |
<< 1501 ~ 1600 «h¦^ÂÐ >> |